


Biomaterials Science

www.rsc.org/biomaterialsscience



ISSN 2047-4830



REVIEW ARTICLE

Mark E. Meyerhoff *et al.*

Recent advances in thromboresistant and antimicrobial polymers for biomedical applications: just say yes to nitric oxide (NO)





Cite this: *Biomater. Sci.*, 2016, 4, 1161

Recent advances in thromboresistant and antimicrobial polymers for biomedical applications: just say yes to nitric oxide (NO)

Yaqi Wo,^a Elizabeth J. Brisbois,^b Robert H. Bartlett^b and Mark E. Meyerhoff*^a

Biomedical devices are essential for patient diagnosis and treatment; however, when blood comes in contact with foreign surfaces or homeostasis is disrupted, complications including thrombus formation and bacterial infections can interrupt device functionality, causing false readings and/or shorten device lifetime. Here, we review some of the current approaches for developing antithrombotic and antibacterial materials for biomedical applications. Special emphasis is given to materials that release or generate low levels of nitric oxide (NO). Nitric oxide is an endogenous gas molecule that can inhibit platelet activation as well as bacterial proliferation and adhesion. Various NO delivery vehicles have been developed to improve NO's therapeutic potential. In this review, we provide a summary of the NO releasing and NO generating polymeric materials developed to date, with a focus on the chemistry of different NO donors, the polymer preparation processes, and *in vitro* and *in vivo* applications of the two most promising types of NO donors studied thus far, *N*-diazoniumdiolates (NONOates) and *S*-nitrosothiols (RSNOs).

Received 18th April 2016,

Accepted 11th May 2016

DOI: 10.1039/c6bm00271d

www.rsc.org/biomaterialsscience

Blood-contacting biomaterials are an integral part of various biomedical devices, ranging from simple catheters to intravascular grafts to extracorporeal circuits and membrane oxygena-

tors, that offer lifesaving treatments to thousands of patients every day. The incorporation of these blood-contacting materials is usually complicated by foreign body response that is initiated by the coagulation cascade¹ (see Fig. 1).

Exposure of blood to foreign materials will cause plasma proteins, such as Factor XII and Factor XI, to be activated and adhere to the polymer surface. The activated protein will interact with platelet surface membrane receptor GPIIb/IIIa, that

^aDepartment of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.

E-mail: mmeyerho@umich.edu; Tel: +1 (734) 763-5916

^bDepartment of Surgery, University of Michigan Medical Center, Ann Arbor, MI 48109, USA



Yaqi Wo

Yaqi Wo is currently pursuing her Ph.D. in Chemistry under Dr Mark E. Meyerhoff at University of Michigan. She received her B.S. degree in Chemistry from Xiamen University, China. Her primary area of research is to develop and characterize novel nitric oxide (NO) releasing polymeric materials. She is also conducting *in vitro* and *in vivo* testing to evaluate the hemocompatibility and/or antibacterial properties of these new

materials/devices (e.g., intravascular catheters, urinary catheters and wound healing patches).



Elizabeth J. Brisbois

Elizabeth J. Brisbois earned her Ph.D. degree in Chemistry at the University of Michigan in 2014. Her dissertation work focused on the design and characterization of novel nitric oxide releasing polymers, based on *S*-nitrosothiols and diazeniumdiolates, for improved hemocompatibility applications. She is currently a National Institutes of Health Postdoctoral Fellow at the University of Michigan Medical School and has also been

awarded with a MICHR Postdoctoral Translational Scholars Program career development award. She is now studying electrochemical methods to generate nitric oxide for potential biomedical applications.





Fig. 1 Simplified schematic of the blood-coagulation cascade, where both intrinsic (surface contact) and extrinsic (tissue factors) pathways converge and ultimately form thrombus (modified from review by Sefton *et al.*²).

can bind with fibrinogen, von Willebrand Factors (vWF), fibronectin, and vitronectin, which ultimately leads to platelet conformational changes, subsequent release of intracellular agents (*e.g.*, Factor V, VIII and Ca^{2+} , *etc.*), and initiates platelet activation and aggregation (intrinsic pathway).^{2,3} Further, surgical procedures that utilize these devices have the potential to injure the vessel wall, disrupt blood homeostasis and release tissue factor, also causing platelet activation and concomitant conformational changes as well (extrinsic pathway).^{1–6} Both pathways converge and trigger the coagulation cascade as the activated platelets bind with fibrinogen and other clotting factors. Fibrinogen forms insoluble fibrin, which traps red

blood cells and ultimately forms a thrombus within a matter of hours^{7,8} (see Fig. 2).

In addition to thrombus formation, bacterial infection is also often associated with the use of many biomedical devices. The rise of hospital-acquired infections, also known as nosocomial infections, is a growing concern in healthcare industry. It was reported that an estimated 1.7 million patients suffered from healthcare-associated infections (HAI) in the U.S. hospitals in 2002 and the number of HAI deaths was 98 987 patients, including 30 665 resulting from bloodstream infections.^{9–15} Device-related infections are the result of bacteria adhesion to the biomaterial surface. After planktonic bac-



Robert H. Bartlett

Robert H. Bartlett earned his M.D. with honors in 1963 from the University of Michigan Medical School and is currently Professor Emeritus in Department of Surgery at the University of Michigan. He is best known for his clinical innovations and development of ECMO, extracorporeal membrane oxygenation, that has saved thousands lives since 1975. His contributions have been recognized by numerous awards, including the American College of

Surgeon's Sheen Award for Research, Medal of Special Recognition from the National Academy of Surgery of France, and Medallion of Scientific Achievement from the American Surgical Association. He is also a member of the Institute of Medicine of the National Academy of Science.



Mark E. Meyerhoff

Mark E. Meyerhoff earned his Ph.D. degree in Chemistry at the State University of New York at Buffalo, in 1979. He joined the Department of Chemistry at the University of Michigan in 1979 as assistant professor and is currently the Philip J. Elving Collegiate Professor of Chemistry. His active research is in the areas of novel electrochemical and optical chemical sensors for anions and gas detection as well as developing new nitric oxide

(NO) release polymers to improve the biocompatibility of implantable biomedical devices. He has been recognized with many awards, including the Ralph N. Adams Award in Bioanalytical Chemistry, the Charles N. Reilly Award in Electroanalytical Chemistry and the ACS Analytical Chemistry Award in Electrochemistry.




Fig. 2 Simplified representation of the processes that lead to thrombus formation on the surfaces of blood-contacting biomedical devices.




Fig. 3 Representative processes involved in biofilm formation and bacteria dispersion.

teria initially colonize onto the surfaces of polymeric devices, cells start to grow into colonies, and then hydrated matrices of extracellular polymeric substances (EPS) are formed, also known as biofilms,^{16–18} (see Fig. 3).

The EPS holds the bacterial cells together in a mass and firmly attaches the cells to the underlying surface. Ultimately, a mature biofilm will periodically release bacteria cells from the biofilm colony into the surrounding medium. Of note, the EPS is both a physical and a chemical barrier to antibiotics and significantly retards their rate of penetration that makes conventional antibiotic treatment for such infections ineffective. Further, the EPS can possibly foster antibiotic-resistant bacterial gene mutations.¹⁹ Ideally, all biomedical devices should be able to prevent bacterial colonization on their surfaces, especially within the first 6 h of blood exposure, which is identified to be the most susceptible and most “decisive period” for the success of a long-term implant.²⁰ Thrombus and bacteria biofilm formation cause device failure, which in many cases can only be solved by device removal and replacement. Besides patients suffering, the increased healthcare costs associated with these infections has also created a significant economic burden.²⁰

The clinical problems of thrombus and infection described above have triggered substantial interest among scientists to develop new and more effective ways to create antithrombotic and antibacterial polymeric surfaces for biomedical devices, especially those in direct contact with blood (*e.g.*, intravascular catheters, vascular grafts, *etc.*).

Current strategies for prevention of thrombosis

Actively releasing anticoagulants to block the innate coagulation cascade

In a clinical setting, in order to prevent surface-induced thrombosis during cardiopulmonary bypass, hemodialysis, and angioplasty, anticoagulants are routinely administered, the most commonly used one being heparin.^{2,21} However, systemic heparin administration can lead to hemorrhage and thrombocytopenia. Localized release of heparin with concentrations that are not tolerable at the systemic level may be applied with minimal side-effects.^{22,23} To date, several approaches have been pursued to achieve localized heparin activity at the

surface of implanted devices including the creation of heparin-releasing polymer surfaces *via* ionic bonding,^{22,24–26} physical dispersion^{27–30} and solution swelling,^{22,31,32} as well as heparin-immobilized polymer surfaces.^{33–36} For example, Gutowska *et al.*²² described a novel thermosensitive heparin-releasing poly(*N*-isopropylacrylamide) (poly(NiPAAm)) coating for prevention of surface-induced thrombosis on polyurethane catheters. Poly(NiPAAm) has a lower critical solution temperature (LCST) in aqueous solution, around 32 °C, which enables it to swell when immersed in a heparin solution at low temperature (*e.g.*, room temperature, RT) and uptake this polyanionic drug. When the temperature is higher than LCST, the swollen coating will collapse dramatically and release heparin. Both the heparin impregnated and control PU catheters were inserted into saphenous veins in a canine model for 1.5 h, and the heparin-releasing PU catheter surfaces demonstrated a significant reduction of thrombus formation after contact with the venous blood. This was demonstrated by SEM images of the explanted catheters when compared to the appropriate controls. Heparin typically has low solubility in organic solvents, but this swelling method introduced the possibility of solution absorption in water and loading of a relatively large amount of the drug into the swollen polymer chains. This method also offers flexibility for the amount and type of anti-coagulant drugs that can be loaded into various thermosensitive coatings.²² However, the heparin release kinetics for this system are relatively fast, with the release rates of 1 µg per cm² per h for up to 6 h. Therefore, the potential application of this material is limited to preventing thrombosis formation in short-term applications, such as for angiography catheters, *etc.*

Heparin has also been covalently linked to the surface of vascular grafts *via* end-point immobilization and this approach has been commercialized for expanded polytetrafluoroethylene (ePTFE) and Dacron grafts.^{37–39} The key to the success of heparin-immobilized polymers depends on the covalently bound heparin remaining flexible enough to bind antithrombin III in order to prevent fibrin formation and the ultimate blood clot.³ The literature on immobilization of heparin is vast and has been reviewed extensively elsewhere.^{37,40} However, due to their very short half-life,⁴¹ heparinized polymer surfaces still suffer a great challenge when it comes to long-term *in vivo* applications. Other anticoagulants such as thrombomodulin,³⁶ direct thrombin inhibitors (*e.g.*, hirudin⁴² and argatroban⁴³), or antiplatelet drugs (*e.g.*: prostacyclin (PGI₂))^{36,41,42} have also been immobilized onto polymer surfaces to increase their hemocompatibility, with varying degrees of success.

Chemical modification of the polymer surface to reduce protein adsorption

It is widely known that the first step that initiates activation of the coagulation cascade is protein adsorption (especially fibrinogen and von Willebrand factor; see Fig. 2) to the surface of a blood-contacting medical device. This knowledge has led to many years of research in developing approaches to modify polymer surfaces that focus on reducing such non-specific

protein adsorption. Some examples include immobilizing a layer of blood-compatible hydrogels on the device surfaces, such as poly(vinyl alcohol) (PVA), polyacrylamide (PAAm), poly(*N*-vinyl pyrrolidone) (PNVP), poly(hydroxyethyl methacrylate) (PHEMA), poly(ethylene oxide) (PEO), poly(ethylene glycol) (PEG), poly(ethylene glycol) monomethyl ether (PEGME), and cellulose.^{3,22,44} Hydrogels are water-swollen polymeric networks containing chemical or physical cross-links and were first used initially as soft contact lenses in the late 1950s.⁴⁵ Due to their hydrophilicity and excellent water retention properties, they have the natural tendency to prevent cell and protein adhesion and are considered to be very biocompatible and desirable in biomedical applications. For example, immobilization of PEG (–CH₂CH₂O–) is a widely used method to modify traditional polymer surfaces employed in the medical field, such as plasticized poly(vinyl chloride) (PVC) and polyethylene (PE), *etc.*^{46–49} PEG is a non-toxic water-soluble polymer approved by the U.S. Food and Drug Administration (FDA) for internal consumption.⁵⁰ Lakshmi *et al.*⁴⁶ were among the first to graft PEG 4000 onto medical grade PVC sheets and conducted thrombogenicity studies to evaluate platelet adhesion using platelet rich plasma (PRP) and whole blood clotting time with fresh rabbit blood. The scanning electron microscope (SEM) images clearly indicated more platelet adhesion to the bare PVC sheet than the PEG-grafted ones. The PEG grafting also extended the whole blood clotting time from 20 min to more than 70 min as determined by the hemolysis assay. Balakrishnan *et al.*⁴⁷ later demonstrated success using bulk modification of PVC resin with PEG 600 that yielded greatly reduced solid/water interfacial free energy and platelet adhesion in *in vitro* PRP studies. This study expanded the anti-fouling chemistry from surface modification on a finished product to bulk synthesis. However, studies conducted by Sefton and coworkers, who used PEG immobilized PVA hydrogel coated PE tubing in an *ex vivo* canine arteriovenous (AV) shunt, reported that neither the PEG grafted or control PVA tubing could maintain circulating platelet levels after 4 d.⁴⁹ Heparin and hydrogel modified surfaces are the most commonly studied approaches for achieving thromboresistant surfaces. For further breadth, readers are guided to reviews that highlight additional approaches developed thus far, such as endothelial cell coated-surfaces, albumin-coated surfaces, pyrolytic carbon-coated surface, phosphorylcholine surfaces, elastin-inspired surfaces, *etc.*^{3,42,51–53}

Current strategies for creating antibacterial surfaces

Surfaces that resist bacteria and reduce initial attachment

Bacteria attachment to device surfaces is the first step required for biofilm formation. Therefore, using biomaterial surfaces that resist bacteria attachment is an intuitive solution to this problem.⁵⁴ Super-hydrophobic polymer surfaces, such as very smooth silicone, polyurethane, polytetrafluoroethylene (PTFE), poly(vinyl chloride) (PVC), and polyethylene (PE), that have

water contact angles larger than 150° , low surface energy,^{55,56} as well as unique water repellent⁵⁷ and self-cleaning abilities,⁵⁶ are known to have resistance to microbial cell adhesion during short-term applications.⁵⁸ Hydrophilic surface modifications, such as the PEG modified surfaces discussed above, have also been widely characterized in the literature and have demonstrated excellent anti-adhesive properties for bacteria cells and proteins.⁴⁴ However, the susceptibility of PEG to oxidative damage, especially in the presence of O_2 , transition metal ions or certain enzymes *in vivo*, has limited its long-term application in complex media.^{59,60} Some studies have demonstrated that polymer surfaces with segmented block co-polymers (hard and soft domains) that result in phase-separated structures also exhibit less bacterial adhesion and cell attachment.^{61–63} Overall, however, passive surfaces without functional active agents may not be ideal for long-term applications because these surfaces may eventually become contaminated due to defects during preparation or deterioration of the coating when in contact with physiological fluids.^{3,4,64}

Surfaces that disperse or detach biofilms

Biofilm dispersal is a promising area of research that focuses on how to inhibit biofilm formation using dispersal agents, which induce biofilm bacteria to detach and return to their planktonic form. Several studies have found that bacteria naturally produce biofilm dispersal agents when the community senses a quorum, signaling the detachment process.⁵⁴ These agents include D-amino acids,⁶⁵ *cis*-2-decenoic acid (C2DA),^{16,18,54} peptides and various enzymes (*e.g.*, dispersin B), *etc.*^{54,66} However, most mechanisms of action of these compounds are still unclear, which hinders further development and application in this field. Many researchers have studied the effects of these dispersal agents *in vitro*, by adding the agents directly to pre-formed biofilm in petri dishes or bioreactors.⁶⁷ Jennings *et al.* attempted to load C2DA into chitosan sponges for localized delivery by initially immersing the sponges into 1 mL of 100 mg per mL C2DA in 10% ethanol.⁶⁸ The release of C2DA was determined by HPLC and its release lasted 5 d ($200\text{--}1000\ \mu\text{g mL}^{-1}$) with a burst of C2DA release on day 1. The anti-biofilm efficiency of the C2DA loaded chitosan sponge was tested against clinical isolates of methicillin-resistant *Staphylococcus aureus* (MRSA) and the results showed that C2DA at a concentration (in the sponge) at or above $500\ \mu\text{g mL}^{-1}$ can inhibit bacterial growth. Current research in this field is aimed at developing vehicles for the controlled and sustained release of such biofilm dispersal agents.⁵⁴

Surfaces that have bactericidal functionalities

The most common mechanism of creating functional antibacterial surfaces is through a bactericidal effect, which includes employing a vast collection of approaches involving quaternary ammonium compounds (QACs)^{64,69–71} and other polycations (*e.g.*, organometallic dendrimers⁷² and chlorhexidine⁷³), metal ions (*e.g.*, silver,^{74,75} copper,⁷⁶ titanium,⁷⁷ *etc.*), locally released antibiotics (*e.g.*, gentamicin^{66,78,79}) or bactericidal agents (*e.g.*, bacteriophages,^{54,80,81} protein synthesis inhibitors,⁶⁶ antibac-

terial enzymes such as lysozyme,^{64,82} antibacterial peptides,^{83–85} natural biomolecules such as chitosan^{86–88} and herbal extracts (*e.g.*, flavanones and chalcones,⁸⁹ *etc.*) and inducing oxidative stress.^{72,90} In general, the mechanisms of bactericidal surfaces are: (1) contact-based bactericidal activity (*e.g.*, QAC, *etc.*) which affects the ion-exchange processes and cause general perturbations that destabilize the cytoplasmic membranes of bacteria, resulting in leakage of the intracellular fluid; and (2) release-based bactericidal (*e.g.*, metal ions, antibiotics, *etc.*), which damage the bacterial cell membrane as well as disrupt the function of bacterial enzymes, DNA, proteins and cell membranes.⁶⁴ A problem, however, with many bactericidal surfaces is the attachment of dead microorganisms remaining on the antibacterial coatings, which can trigger immune response and inflammation, as well as block a given coating's active functional group.

In recent years, in order to achieve improved antibacterial and anti-fouling efficacy, many researchers have developed polymeric surfaces that combine more than one of the antibacterial functionalities mentioned above; for example, creating a surface that not only can attach and kill bacteria but also be able to release any adhered dead bacteria debris. Toward this goal, many pH,^{59,82,91} thermo,⁹² or electrical voltage⁹³-responsive polymers, that can be controllably extended or collapsed or altered in their charge carrying properties have been developed. They are often termed "stimuli-responsive smart antibacterial surfaces". Jiang and coworkers developed a cationic poly(*N,N*-dimethyl-*N*-(ethoxycarbonylmethyl)-*N*-[2'-(methacryloyloxy)ethyl]-ammonium bromide) that has a quaternary ammonium group and was grafted onto a gold surface by surface-initiated atom transfer radical polymerization.⁵⁹ The cationic surface can kill 99.9% of *E. coli* bacteria when exposed to a suspension of 10^{10} cells per mL for 1 h, and then it hydrolyzes into a nonfouling zwitterionic surface and releases 98% of the bacterial residue after 8 d at 37°C and pH 10.0. This is only a one-time transition between cationic and zwitterionic surface; therefore, in order to achieve a fully reversible "kill and release" functional surface, a surface with morpholinone derivatives that can be switched repeatedly between two equilibrium states was developed by the same authors.⁹¹ In neutral or basic aqueous phase, the surface will release dead bacteria and at the same time resist bacteria adhesion. However, under acidic conditions (*e.g.*, in acetic acid for 20 h), the surface will regenerate bacteria-killing function by reforming the quaternary ammonium functional group.

Of note, there are some limitations of this method of using pH change to alter antimicrobial properties of a surface. These include: (1) this surface can kill bacteria attached on the surface while it is dry, since a wet version of this surface is generally resistant to bacterial attachment, suggesting this method mainly works for applications that prevent airborne bacteria; and (2) the requirement of changing environmental pH to achieve surface functionality may be difficult *in situ* with certain biomedical applications (*e.g.*, blood-contacting devices). Most recently, Chen and coworker developed an on-demand switchable and repeatable antibacterial surface. They

used a silicone nanowire grafted pH-responsive poly(methacrylic acid) (SiN-PMAA) for loading a natural antibacterial agent (*i.e.*, lysozyme enzyme), enabling killing of bacteria and releasing dead bacteria debris when alternating the environmental pH between 4, 7 or 10, respectively. The SiN-PMAA surface exhibits a high capacity for binding lysozyme at acidic pH, but can release the majority of the adsorbed lysozyme that serves as biocide to kill bacteria attached to the surface or suspended in solution at neutral pH, and then release the dead bacteria to provide a self-cleaning process when the environment pH is increased to a basic value. This dynamic reservoir concept may serve as the foundation for engineering multifunctional surfaces that could find many practical applications (such as biocatalysis and biosensing) in both biomedical and biotechnology fields. However, achieving the needed changes in pH within blood, which is a relatively strong buffer, will be more challenging.

Lastly, bacterial interference is a different concept that uses active bacteria (either probiotic bacteria^{54,94,95} or bacteria with less virulence^{96–98}) to inhibit the targeted bacteria by competing for common resources in the same environment. This approach can be leveraged to prevent infections from exogenous sources. Trautner *et al.* reported a prospective clinical trial of using nonpathogenic bacteria colonized on urinary catheters in patients who require indwelling catheter drainage, to examine their effect in preventing bacteriuria commonly present in patients with indwelling urinary tract catheters.⁹⁸ Commercial urinary catheters were incubated in broth of *Escherichia coli* (*E. coli*) HU2117, a genetic strain that can cause persistent colonization without symptomatic infection,⁹⁹ for 48 h before insertion into patients for 28 d. The patients' urine samples were collected at various time points until *E. coli* HU2117 was no longer detected. Ten (83%) out of 12 subjects were successfully colonized with *E. coli* HU2117 for 14 d or more (range, 15–165 d) after inoculation by insertion of the catheter. One patient had urinary tract infection (UTI) symptoms caused by *Pseudomonas* but none of the patients experienced UTI attributable to the colonization of *E. coli* HU2117. The overall rate of symptomatic UTI for this study was 0.15 cases per 100 patient-days of colonization, compared to the reported rate of 2.72 cases per 100 patient-days, which suggested that this organism may have a protective function in patients who used the *E. coli* colonized catheters.¹⁰⁰ However, a larger study group is needed to test the safety and efficacy of *E. coli* HU2117 coated catheters in highly problematic populations.

Creating dual-functionality hemocompatible surfaces

The ultimate truly hemocompatible polymer for blood-contacting biomedical devices should have both antithrombotic and antibacterial functionalities. Many dual-functional materials have been investigated, including zwitterion-based surfaces, submicron-patterned surfaces, and surfaces with multiple functional moieties, *etc.*

Zwitterionic polymers are polymers with equimolar number of homogeneously distributed anionic and cationic groups on their polymer chains, that form a hydration layer on the surface of the material through electrostatic interaction and therefore resists plasma protein and bacterial cell adhesion.^{64,101,102} An alternative strategy towards creating hemocompatible surfaces is to change the polymer's surface topography, thereby mediating subsequent biological responses. Creating a submicron-textured surface can dramatically reduce the accessible contact area for platelets or bacteria to interact with the surface, thereby minimizing the opportunities for bacteria and platelet adsorption.^{103–105} Polymers that combine multiple functional groups on one surface have also been tested, such as combining a synthetic heparin-mimetic polymer or hydrophilic polymer brushes (*e.g.*, PEG) with antibacterial quaternary compounds (QAC) or Ag nanoparticles.^{106–108}

Despite some successes in the research laboratory with the methods reported above, newer approaches to reduce the possibility of thrombus and/or infection on indwelling device surfaces are still in great demand within the medical community. Therefore, the main focus of the remaining content of this review is the utilization of polymer-based NO delivery to prepare dual functioning antithrombotic and antibacterial surfaces for biomedical applications.

Nitric oxide (NO) to the rescue

Nitric oxide (NO), a diatomic free radical, was identified as the endothelium-derived relaxation factor (EDRF) in the Nobel Prize-winning discovery by Ignarro, Furchgott, and Murad in 1987.^{20,109–114} Many researchers have later unveiled NO's various physiological functions in the human body, including preventing platelet activation and adhesion, inhibiting bacterial proliferation and biofilm formation, enhancing endothelization, signaling in the immune system's response, and promoting angiogenesis and the wound healing process.^{113,115–118}

The human body synthesizes a large quantity of bio-regulatory NO from the substrate L-arginine *via* three distinct isoforms of nitric oxide synthase (NOS), including endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS).^{119–121} The NO produced by eNOS contributes to the thromboresistant properties of the endothelial lining of blood vessels by inhibiting platelet activation. The activation of platelets is mediated by NO through the soluble guanylate cyclase (sGC) pathway. NO binds to the heme iron moiety of sGC and subsequently increases intracellular concentrations of cyclic guanosine monophosphate (cGMP).^{122,123} In addition, the cGMP increases cyclic adenosine monophosphate (cAMP) levels indirectly through phosphodiesterase III, which will also decrease the intracellular calcium concentration. The NO activated sGC ultimately results in reduced intracellular calcium, inhibition of platelet phosphoinositide 3-kinase (PI3), and reduced affinity as well as number of surface membrane fibronectin binding sites on platelets (GPIIb/IIIa).^{118,122–127} It has also been suggested that many NO-related species are essential

for NO's potent antimicrobial effects. First, NO can react with superoxide (O_2^-)¹²⁸ and form peroxyxynitrite ($OONO^-$), which is a lethal oxidizing agent and can induce oxidative stress, nitrosate amino acids and thereby alter protein functionality, oxidize and break DNA strands, and cause cell membrane damage to the bacteria it comes in contact with *via* lipid peroxidation.^{20,128–130} A second possible route reported for NO mediated cytotoxicity relies upon the formation of *S*-nitrosothiols (RSNO) in which after oxidation of NO to N_2O_3 the N_2O_3 can react with sulfhydryl groups on cysteine residues of membrane proteins to create RSNO structures that alter protein functionality, leading to cell stasis or cell death.¹⁰⁹ Indeed, NO released or generated from polymer matrices has been shown to have similar antiplatelet and antimicrobial effects, as further described in detail below.

Some surgery interventions or trauma that destroys the endothelial lining, as well as certain vascular diseases, will lead to an increased level of superoxide anions and that react with NO and reduce its bioavailability.^{120,131} Reduced NO levels are associated with many health complications and/or diseases, such as high blood pressure, deep vein thrombosis, intimal hypertension, restenosis, endothelial dysfunction, and prolonged wound healing times in diabetic patients, *etc.*^{1,132,133} There are three main strategies for increasing NO bioavailability: (1) by participating in physical exercise and controlling certain dietary components (*e.g.*, nitrate-rich diet);^{133,134} (2) by administering drugs that alter the enzymatic production of NO through nitric oxide synthases (NOSs) and increase the biosynthesis of NO endogenously;¹¹⁸ and (3) by using modified polymeric materials that can actively deliver NO exogenously to the sites of interest.^{3,110,111} Various NO-related drugs have been used in the clinical settings for many years: nitroglycerin (converted to NO by enzymes) for chest pain, sodium nitroprusside for controlling blood pressure, and molsidomine for pulmonary hypertension.¹³² This has triggered substantial interest in developing polymers that can be functionalized as an artificial endothelium-like surface to therapeutically deliver NO locally at the polymer/blood interface.

Since NO is highly active *in vivo* (with a short-half life on the order of seconds due to its rapid reaction with oxyhemoglobin, oxygen, and thiols, *etc.*), many NO donors have been synthesized and used for achieving the goal of prolonged and controlled NO delivery. Some examples include organic nitrates or nitrate esters (*e.g.*, nitroglycerin or glyceryl trinitrate (GTN) and pentaerythrityl tetranitrate (PETN)), metal-NO complexes (*e.g.*, sodium nitroprusside), nitrite, *N*-diazoniumdiolates (NONOate), and *S*-nitrosothiols (RSNO),^{135–141} (see Fig. 4). Nitroglycerin, the most commonly used organic nitrate for clinically treating hypertension and angina pain, is known to release 1 mole equivalent of NO upon bioactivation by mitochondrial aldehyde dehydrogenase (mtALDH).¹¹² However, patients often develop nitrate tolerance (tachyphylaxis) after prolonged use because the reactive oxygen species generated by nitroglycerin can oxidize the thiol group of the mtALDH and result in enzyme dysfunction.^{112,142–144} This low bioavail-

ability limits nitroglycerin's use as an efficient NO donor and complicates clinical treatments.

Metal NO complexes (metal nitrosyls) represent another class of NO donors used in biological testing. Many different metal NO complexes have been reported, including manganese,^{109,137} iron¹⁴⁵ and ruthenium-NO^{109,112,137} complexes, with sodium nitroprusside ($Na_2[Fe(CN)_5NO]$, SNP) being the most common. SNP is often used as a potent vasodilator in hypertensive emergencies,¹⁴⁵ and releases NO in the presence of reducing agents (*e.g.*, thiol-containing compounds such as cysteine or glutathione) or by illumination with near-infrared or visible light.^{112,121,145} However, cellular toxicity concerns due to the release of cyanide and cytotoxic peroxyxynitrite as byproducts have made metal nitrosyl complexes less attractive as medicinally used NO donors.^{112,141}

Reduction of nitrite can generate NO *via* both enzymatic (nitrite reductase, xanthine oxidoreductase, *etc.*) and non-enzymatic (gastrointestinal acid, ascorbate, myoglobin, *etc.*) pathways.¹³³ Recently, it was demonstrated that nitrite can also be used to generate NO *via* electrochemical reduction at an electrode surface with either Cu(I) ion generated from oxidation of Cu^0 (ref. 146 and 147) or *via* the use of Cu(II)-ligand complexes that mimic the active site of nitrite reductase (*e.g.*, Cu(II)-tri(2-pyridylmethyl)amine, Cu(II)TPMA).¹⁴⁸

Many researchers over the past two decades have focused on using *N*-diazoniumdiolates (NONOates) and *S*-nitrosothiols (RSNOs) as leading candidates for controlled NO delivery due to their relatively high stability, their ability to spontaneously release NO under physiological conditions (*e.g.*, no enzyme required) in a predictable manner, and their higher bioavailability *in vivo*.^{3,121,136} Furthermore, the tissue and metabolite independent release also avoids the build-up of tolerance over time, which makes these agents more suitable for biomedical applications.

N-Diazoniumdiolates (1-amino-substituted diazen-1-ium-1,2-diolate) are a class of NO donor molecules formed by reactions between primary or secondary amines with NO under high pressure (*e.g.*, 5 atm) in the presence of base (either an unreacted amine substrate or an added metal alkoxide base) at low temperatures.^{1,137} These species are able to generate two mole equivalents of NO per mole of donor, *via* a proton-driven reaction (hydrolysis), in the physiological environment such as when the compound is exposed to blood or tissue fluids (see Fig. 5). NONOates can also release NO *via* thermal, photochemical or enzymatically (*e.g.*, esterase) reactions.^{137,149}

The half-lives of the synthesized NONOates strongly depend on the structure of the amine precursors and hydrogen bonding stabilization from additional amines within the molecule. It has also been reported that hydroxyl groups within the donor molecule, or the matrix it is within, can also contribute to the hydrogen bonding with the diazeniumdiolates.^{150,151} For example, half-lives can range from the shortest reported $t_{1/2}$ of 1.8 s for the diazeniumdiolated amino acid proline (PROLI/NO) to $t_{1/2}$ of 20 h for diethylenetriamine (DETA/NO).^{136,137} One drawback of the diazeniumdiolate compounds is that they may potentially form carcinogenic nitrosamines.^{152,153} Batchelor *et al.* synthesized more lipophilic




Fig. 4 Structures of commonly studied NO donors in biomedical applications, (a) sodium nitroprusside; (b) potassium nitrosylpentachlororuthenate; (c) nitroglycerin; (d) pentaerythryl tetranitrate; (e) diazeniumdiolate of *N*-(6-aminohexyl)aminopropane; (f) diazeniumdiolate of *N,N'*-dibutylhexamethylenediamine; (g) *S*-nitrosoglutathione; (h) *S*-nitroso-*N*-acetylpenicillamine.




Fig. 5 *N*-Diazeniumdiolates (NONOates) formation and decomposition.

NONOates for use in reducing the NO donor leaching into blood from polymers that had been doped with such NO donors.¹⁵⁴ Since the NO release process produces a lipophilic amine byproduct that increases the pH of organic phase, many additive compounds (such as tetraphenylborate or other borate derivatives¹⁵⁴) have been included within the organic polymeric phase to serve as counter ions for organic ammonium cations (when amines form after NO release and proton is extracted into the polymer to create the ammonium species) and thereby partly prevent a pH increase within the organic polymer phase. This can greatly prolong the NO release lifetime from such NO donors when incorporated into biomedical polymers. Unfortunately, the borate additives are not ideal because of their inability to extend the NO release to more

than a few days and their cytotoxicity toward endothelial cells.^{155,156} Therefore, Handa *et al.*^{155,156} as well as Cai *et al.*¹⁵⁷ studied various poly(lactic-co-glycolic acid) (PLGA) additives with different hydrolysis rates as a means to slowly produce protons within the organic polymer phase that can continue to drive NO release reaction from NONOates. PLGA is a biocompatible and biodegradable polymer, with tunable mechanical properties and wide range of erosion times. Further, it is already approved for use by the FDA for the development of devices for controlled delivery of small molecule drugs, proteins and other macromolecules.¹⁵⁸ These studies demonstrated that the presence of PLGAs in the base polymer containing diazeniumdiolate species can extend NO release under physiological conditions for up to at least 2 weeks.

S-Nitrosothiols (RSNO) represent an endogenous class of NO donors and natural transporters of NO within tissues and blood.^{121,159} Such molecules include S-nitrosoalbumin (SNO-Alb), S-nitrosohemoglobin (SNO-Hb), S-nitrosocysteine (SNO-Cys) and S-nitrosogluthione (GSNO).¹⁶⁰ RSNOs can be synthesized *via* the thiol nitrosation reaction (such as nitrous acid and alkyl nitrite, *etc.* in an acidic environment).¹⁴¹ Owing to the natural occurrence of RSNOs *in vivo*, these molecules pose a relatively low risk of toxicity to cells/tissues in comparison to NONOates. The transnitrosation reaction transfers the NO⁺ functional group from an RSNO species to another existing free thiol, thus achieving a circulating unlimited supply of NO *in vivo*.¹⁶¹

RSNOs have characteristic UV-Vis spectra. In general, they appear green for tertiary RSNOs (such as S-nitroso-N-acetylpenicillamine, SNAP) or pink for primary and secondary RSNOs (such as SNO-Cys, S-nitroso-N-acetylcysteine (SNAC) and GSNO). There are two primary bands in the UV-Vis spectra. The strong band in the UV region is between 330 and 350 nm ($\epsilon \sim 10^3 \text{ M}^{-1} \text{ cm}^{-1}$), which is attributed by the $n_o \rightarrow \pi^*$ transition.^{141,162–164} A weak band in the visible region is between 550 to 600 nm ($\epsilon \sim 20 \text{ M}^{-1} \text{ cm}^{-1}$), which is attributed to the $n_N \rightarrow \pi^*$ transition.¹⁴¹ It is known that RSNOs can release NO *via* multiple pathways.^{164–169} Thermal or photo-initiated decomposition will lead to homolytic cleavage of the S–N bond, and form thiyl and NO radicals, where thiyl radical (RS[•]) will react with another RSNO and generate disulfide (RSSR) and another NO radical. Metal ions (such as copper or ferrous ions)^{170,171} or organoselenium compounds can catalyze RSNO decomposition.^{115,172–174} It is reported that Cu⁺ (generated from reduction of Cu²⁺ by trace amounts of thiol) can react with RSNO and form the corresponding thiolate and Cu²⁺, which then react to regenerate Cu⁺ and a disulfide to continue the catalytic cascade. RSNOs can also react with ascorbate to generate NO *via* two pathways. In one, ascorbate (at low concentration) acts as a reducing agent to generate Cu⁺ from trace copper ion impurities in solution, or at high concentration ascorbate can act as a nucleophile, attacking the nitroso group to generate NO, a thiolate and dehydroascorbate.^{8,175,176} Further, certain enzymes such as copper-containing superoxide dismutase (CuZn-SOD)^{141,177} or the selenium-containing enzyme glutathione peroxidase (GPx)^{141,172,174} can also convert RSNO to NO in the presence of a reducing agent, such as glutathione (GSH) (see Fig. 6).

GSNO and SNAP are two commonly used RSNOs that have been intensively studied in a variety of biomedical applications. GSNO is present in blood endogenously, which makes it innately more biocompatible and attractive for many applications, such as promoting wound healing process in mice or rats.^{178–181} The precursor for SNAP synthesis is N-acetylpenicil-

lamine (NAP), whose ultimate hydrolysis product, penicillamine, is already a FDA approved chelator for treating heavy metal poisoning, such as Wilson's disease.^{182–185} SNAP is reportedly one of the most stable NO donors available, due to its intermolecular hydrogen bonding,^{163,186} and has already been shown to be a very promising candidate for fabricating long-term NO releasing polymeric materials.^{162,163,187} Lipophilic analogs of SNAP (such as N-substituted derivatives of SNAPs) have also been developed by addition of bulky side-chains to N-acetylpenicillamine and preventing Cu⁺ catalysis through steric hindrance.^{188,189} Other lipophilic RSNOs (*e.g.*, S-nitroso-*tert*-dodecyl mercaptan (SNTDM), $\log P = 5.3$)¹⁹⁰ (note: P = partition coefficient of a molecule between octanol and water) with a higher $\log P$ value than SNAP ($\log P = 0.4$)¹⁶³ have been synthesized for reducing the NO donor leaching from the hydrophobic polymer phase.

Polymer-based strategies for NO delivery

For the past two decades, many research groups have focused on developing techniques to deliver NO locally, continuously and efficiently from polymeric devices where blood clotting and/or bacteria infection are major complications. To improve the NO payload and stability, achieve targeted NO delivery through multi-functionalization and elongate NO releasing lifetime, many different scaffolds have been used as NO-releasing or NO-generating vehicles. These include micelles,^{139,191,192} microbubbles,¹⁹³ proteins,^{194–198} liposomes,^{127,199} inorganic nanoparticles (such as silica,^{71,200–204} gold^{205,206}), microparticles,^{199,207} zeolites,^{208,209} metal-organic frameworks (MOFs),^{210–213} dendrimers,^{72,214,215} xerogels,^{216–218} electrospun fibers,^{89,101,219} natural polymers (chitosan,^{86–88,220–222} gelatin,²²³ *etc.*), and other organic polymers (polymethacrylate,²²⁴ polyester,^{225,226} polydimethylsiloxane (PDMS),²²⁷ polysaccharides,^{228,229} hydrogel,^{179,180,230,231} PVA,^{49,232,233} polyurethanes,^{162,163,234,235} and PVC¹⁵⁵). The approaches and benefits of different NO-delivery materials have been highlighted in numerous reviews.^{1,112,121,132,136–139,236} Here, an overview of the most promising polymer-based NO delivery strategies are discussed, including covalently bound NO donors within/on a polymer matrix, physically dispersed NO donors within a polymer matrix, and catalytically generated NO from various RSNO reservoirs in the body (see Fig. 7), and their representative examples in antithrombotic and antibacterial applications are described.

Covalently bound NO releasing polymers

N-Diazoniumdiolates are one of the most studied NO donors, and many polymers with secondary amine groups have been




Fig. 6 S-Nitrosothiol (RSNO) formation and decomposition.




Fig. 7 Three different strategies to fabricate of polymer surfaces that release or generate NO, including physical dispersion of NO donor into polymeric matrix, covalently bound NO donor functionalities onto polymer backbone, or NO generation from endogenous RSNO species in blood by metal catalysts embedded in or covalently bound to the surface of the polymer.

chemically modified to create the NONOate moiety.^{110,111,137} Meyerhoff and coworkers were among the first to link these NO donors to particle fillers (such as fumed silica particles²³⁷) or to the polymer backbone of polymers such as PVC,^{34,238} polyurethane (PU),^{34,111,234} and silicone rubber (SR).²³⁹ Zhang *et al.* synthesized NO-releasing fumed silica (FS) particles (0.2–0.3 μm) by tethering alkylamines onto the surface of the FS particles using amine-containing silylation reagents (coupling efficiency 50–70%), and then converted them to corresponding NONOate groups with final NO loading of *ca.* 0.6 μmol per mg of particle.²³⁷ The half-lives of the particles are significantly longer than the solution phase NO donor analogs, owing to the fact that a large quantity of amines present at the particle surface can increase the local pH, which then reduces the NO release rate. Of note, when local pH decreases significantly, it results in partial release of the stored NO due to the proton-driven NO release mechanism. Therefore, some methods utilize additional acid-generating compounds to facilitate continual release of the entire NO payload.

Keefer and coworkers were one of the earliest groups to covalently attach a diazeniumdiolate species to the backbone of poly(ethylenimine) (PEI) to form PEI/NONOate, which later was used to provide a flexible NO release coating for PTFE vascular grafts.²⁴⁰ The NO release from the sample was at a relatively constant rate (0.5 $\text{pmol min}^{-1} \text{mg}^{-1}$) for 5 weeks in PBS buffer at 37 °C. In subsequent studies, Saavedra *et al.* prepared methoxymethyl-protected diazeniumdiolated piperazine PVC,²³⁸ however, the NO release rate was slow due to the fact that the NO could only be released from the NONOate group after the hydrolysis of the methoxymethyl protecting group.³⁴

In addition, this PVC film can concurrently release toxic methanol and formaldehyde as byproducts of the methoxymethyl-protecting group, which is undesirable for use as materials in biomedical applications. Zhang *et al.* later incorporated diazeniumdiolated functionalities into more biocompatible silicone rubber.²³⁹ Briefly, a diaminoalkyltrimethoxysilane crosslinking agent (DACA) was reacted with the terminal hydroxyl groups of the PDMS, and then the aminated PDMS macromolecules were cross-linked to each other (condensation-curing) in the presence of ambient moisture before forming the NONOates species at the amine sites (via reaction of the polymer with $\text{NO}_{(\text{g})}$ at high pressure). Likewise, *N*-diazeniumdiolated NO donors have been covalently linked to polyester,²⁴¹ polymethacrylate,²²⁴ polyurethane (PU),^{35,111,234,235} PVA²³³ and other hydrogels²⁴² as well. The synthetic methods are somewhat similar to that described above, with the exception of one type of PU containing a diamine chain extender, where sodium salts (NaX , where X is an anion) are incorporated into the reaction mixture during the NO addition process to facilitate the formation of anionic diazeniumdiolates.¹¹¹

Dendrimers are another class of popular NO delivery vehicles due to their ability to store a large reservoir of NO, have tunable sizes, and to be multi-functionalized for targeted delivery.^{215,243} Stasko *et al.* were the first to modify generation 3 and 5 polypropylenimine dendrimers at their exterior with different amine functionalities that were then converted to diazeniumdiolated dendrimers *via* reaction with $\text{NO}_{(\text{g})}$ at high pressure. The secondary amine/NONOates yield the highest storage capacity for NO, with up to 5.6 μmol NO per mg of polymer, and a NO release duration of >16 h under physiological conditions.²⁴³

Frost *et al.* was the first to modify FS particles (7–10 nm in diameter) with an RSNO functionality,^{200,201} such as *S*-nitrosocysteine-FS (SNO-Cys-FS), *S*-nitroso-*N*-acetylcysteine-FS (SNAC-FS) and *S*-nitroso-*N*-acetylpenicillamine-FS (SNAP-FS). This was accomplished, by tethering the thiol containing amino acids or *N*-acetylpenicillamine thiolactone onto aminopropyl-FS. In these efforts, a total NO loading of up to $1.38 \pm 0.29 \times 10^{-7}$ mol NO per mg particles was achieved. The SNAC-FS and SNAP-FS particles can be blended into polyurethane (PU) or trilayer silicone rubber (SR) matrices to create films that release NO at different rates by tuning the chemical identity, water uptake, or thickness of the PU polymer.²⁰¹ However, the SR films containing SNAC-FS or SNAP-FS in the middle layer do not release NO upon exposure to copper ions or ascorbate in PBS solution because the very high hydrophobicity of the SR blocks the contact between the buffer and the RSNOs.²⁰⁰ However, such films are able to release NO at levels proportional to the intensity of visible light that is allowed to shine on the polymer, providing the first hydrophobic materials that have an external on/off trigger that precisely controls the rate of NO release *via* a photodecomposition reaction. The authors determined that 590 nm light is primarily responsible for the release of NO from the SNAP-FS-SR films. Evidence suggested that 67% of the photoinitiated NO was accounted for by the longer wavelength (590 nm) and 33% by shorter wavelengths (centered around 340 nm). SNAP has also been covalently attached to PDMS,²²⁷ gelatin²²³ and a macrocycle (*e.g.*, cyclam).²⁴⁴ The ability to generate programmable sequences of NO flux from these light-sensitive materials can offer precise spatial and temporal control of the NO release and potentially provides a platform to systematically study, at a fundamental level, the *in vivo* physiological response to implanted devices.²²⁷ Of note, SNAP-cyclam is capable of releasing physiological relevant levels of NO for up to 3 months *in vitro* when blended into poly(*L*-lactic acid) thin films and irradiated by a 385 nm LED, and this represents the longest NO release from SNAP-based polymer films reported to date.²⁴⁴

RSNOs have also been used to form functionalized dendrimers²¹⁴ or hyperbranched polymers (*e.g.*, hyperbranched polyamidoamine (HPAMAM) or hyperbranched polyethers²⁴¹) to achieve a high NO payload. Stasko *et al.* functionalized generation 4 polyamidoamine (PAMAM) dendrimers with *N*-acetylpenicillamine or *N*-acetylcysteine and both macromolecular scaffolds have an NO storage of *ca.* 2 μmol NO per mg polymer after the required nitrosation reaction.²¹⁴

Another category of NO delivering materials with large NO storage capabilities are xerogel films. Riccio *et al.* designed thiol-modified xerogels derived from 3-mercaptopropyltrimethoxysilane (MPTMS) and methyltrimethoxysilane (MTMS).²¹⁷ The subsequent thiol nitrosation generates xerogels with NO loadings up to $1.31 \pm 0.07 \mu\text{mol}$ NO mg^{-1} , and films of these materials are capable of releasing NO for up to 2 weeks under physiological conditions. Similar to *N*-diazoniumdiolates, many other polymer modification studies have been conducted using *S*-nitrosothiols (RSNOs) as well, including those utilizing PDMS,²²⁷ PVA hydrogel,¹⁸⁰ polyester and poly(methylmethacrylate),²²⁵ as the base polymer materials.

Lastly, several biodegradable polymers, such as citrate-based²²⁶ or saccharide-based polymers (*e.g.*, dextran^{228,245} and chitosan^{87,88,221}) provide very attractive scaffolds for NO delivery because of their natural occurrence, biodegradability, tolerability to mammalian cells and accessibility for NO donor functionalization reactions.^{221,245,246} Reynolds and coworkers synthesized two *S*-nitrosated dextran thiomers (dextran-cystamine and dextran-cysteine), with up to $0.205 \pm 0.003 \mu\text{mol}$ per mg NO loading and the capability to release NO for 6 h in PBS buffer at 37 °C. It has been further demonstrated that these dextran-based materials are susceptible to enzymatic degradation by dextranase, and the degradation of dextran derivatives is slower and partial when compared to the unmodified dextran because of the chemical modification of the dextran backbone.²⁴⁵

Physical encapsulation-based NO releasing polymers

Physical encapsulation methods for preparing NO releasing polymers are based on embedding the NO donor within a polymer matrix physically without chemical bonding. This provides a much less complicated method to prepare NO release polymers than covalent attaching NO donors to particle fillers or the polymer backbones. This approach is a more attractive strategy for future commercialization if stable long-term NO release can be achieved by dispersing the NO donor within a polymer matrix. Toward this goal, polymer¹⁹³ or phospholipid²⁴⁷ shelled microbubbles have been developed in recent years to create a hydrophobic microenvironment for NO transportation and therapeutic delivery. Paradossi and co-workers prepared NO-loaded PVA-shelled microbubbles ($4.6 \mu\text{m} \pm 0.4 \mu\text{m}$ diameter and $0.4 \mu\text{m}$ shell thickness) for treating acute vascular disease, such as thrombosis.¹⁹³ The microbubbles were loaded with NO by exposing to gas phase NO at 1.5 bar for 2 h. The NO encapsulation is about 1% of the NO present in the reaction vessel during the loading procedure, with the final content being $3.6 \mu\text{mol}$ per mg microbubbles. The NO release measured by the Griess assay showed that *ca.* 90% of the NO is released during a 50 min period in phosphate buffer saline solution. Ideally, the NO delivery should be controlled and selective bursts at a specific time and place, but the release can also be spontaneous and nonspecific.¹⁹³ Unfortunately, the *in vitro* stability of such NO-loaded microbubbles is relatively low.²⁴⁷

Gas storage in porous materials, such as zeolites, is also another attractive method for medicinal applications. Wheatley *et al.* have used cobalt-exchanged zeolite-A to absorb and store NO ($1.2\text{--}1.3 \mu\text{mol}$ NO per mg zeolite). The NO release was triggered by contacting with water at physiological temperature and pH, replacing the gaseous NO with cobalt-water interactions. These NO-zeolite samples were also blended with powdered PTFE or PDMS to increase their mechanical stability and then pressed as disks for *in vitro* testing. The $t_{1/2}$ values of NO release from zeolite polymer disks was significantly increased (from 340 s for zeolite powder to 509 s for PTFE disk and 3076 s for PDMS disk).²⁰⁸ The results obtained in a platelet aggrego-

metry assay also suggested that the NO-zeolites greatly inhibits platelet aggregation *in vitro*.

Liposomes are also a popular choice to protect and deliver gaseous NO. McPherson and coworkers prepared liposomes encapsulated with NO and argon gas (NO/Ar-ELIP) by a pressured-freeze and thawing method. They used these capsules for attenuating intimal hyperplasia and reducing arterial wall thickness.¹⁹⁹ Other researchers have conducted further studies to encapsulate NO donors within pH¹²⁷ or thermo-sensitive²⁴⁸ liposomes to achieve controlled release. In short, when *N*-diazoniumdiolates are encapsulated within liposomes, pH or temperature fluctuations change the proton influx through the bilayer membrane and subsequently induce a significant NO release. Koehler *et al.* have also encapsulated SNAP within liposome vesicles and then doped the resulting vesicles within xerogels for photosensitive NO release.²⁴⁹

Biodegradable poly(ethylene oxide-*co*-lactic acid) (PELA)²⁵⁰ and poly(lactic-*co*-glycolic acid) (PLGA)^{207,220,250} have also been shown to be suitable vehicles for encapsulating NO donors to prolong the NO release. Yoo and coworkers developed PLGA (5050DLG5E) nanoparticles (NO/PPNPs) with diazeniumdiolated polyethylenimine (PEI) for long term NO release for antimicrobial applications.²²⁰ The average size of the NO/PPNPs was 162 ± 19 nm as confirmed by scanning electron microscopy (SEM), with a NO release capacity of 1.4 μmol NO per mg polymer. The incorporation of PEI/NONOate into hydrophobic PLGA nanoparticle matrix successfully restricts the spontaneous degradation of the NONOate group and extends the NO release lifetime from 12 h to over 6 d.²²⁰ More recently, Lautner *et al.* demonstrated the encapsulation of SNAP into PLGA (RG 503H and RG 504) microspheres (20–125 μm in diameter) using a solid-oil-in water (S/O/W) method²⁵¹ and achieved up to 4 weeks of controlled release of SNAP from PLGA RG 504, which then generates localized NO in the presence of copper(II) and ascorbate.²⁰⁷

Mowery *et al.*³⁴ prepared diazeniumdiolated *N,N*-dimethyl-1,6-hexanediamine (DMHD) or linear PEI and dispersed them into plasticized PVC or PU. Unfortunately, NO donor leaching was observed by HPLC and this raises potential concerns regarding toxicity if nitrosamine formation occurs, and such nitrosamines are also leached into the surrounding aqueous environment. Bachelor *et al.*¹⁵⁴ synthesized more lipophilic dialkylhexamethylenediamine-based NONOates with different alkyl groups (from methyl to didodecyl) which can enhance the retention of potential byproducts within the hydrophobic PVC films and thereby reduce their toxicity threat to biological systems.

Seabra *et al.* incorporated GSNO and SNAC into Synperonic F-127 gel using a 'cold method'²⁵² and formed a hydrogel that contained 0.3 mol of GSNO or 0.6 mol of SNAC per gram of hydrogel.²⁵² Kinetic studies showed that SNAC releases NO thermally 3.6 times faster than GSNO ($11 \pm 0.4 \text{ min}^{-1}$ vs. $3.1 \pm 0.8 \text{ min}^{-1}$); however, approximately 50% of both NO donors had decomposed after only 3 h.²³² Kim *et al.* developed NO-releasing films by dispersing GSNO into biopolymer chitosan, where 75% GSNO remains after storing at room temperature

for 4 weeks. The 20 wt% GSNO/chitosan film released NO over 48 h in PBS buffer at 37 °C.²²² Recently, Brisbois *et al.* discovered that SNAP is exceptionally stable when doped within several low water uptake biomedical grade polymers, such as Elast-eon E2As and CarboSil, and can release NO for up to 3 weeks at physiological conditions.^{156,162} Wo *et al.* later demonstrated that the SNAP in CarboSil mainly exists in crystalline form when the SNAP concentration exceeds its solubility in the polymer. Ultimately, a slow crystal dissolution process leads to its long-term NO release under physiological conditions.¹⁶³ Additionally, this crystal-polymer composite is very stable during storage for at least 8 months, not only because of the hydrophobicity of the CarboSil polymer that limits water diffusion primarily to only the polymer surface, but also because the crystalline SNAP is stabilized by intermolecular hydrogen bonds.^{163,253}

In order to apply NO release to any pre-made or off-the-shelf biomedical devices, Colletta *et al.*¹⁹ developed a simple solvent impregnation method to load SNAP into commercially available silicone Foley urinary tract catheters at room temperature. This impregnation process takes place under very mild conditions, which is beneficial because, like many NO donors, SNAP or its analogs are sensitive to high temperatures used during industrial catheter extrusion processes. In this approach, SNAP or a SNAP analog is dissolved in an organic solvent that can swell the polymer to a great extent without dissolving it, and as the polymer uptakes the solvent, the NO donors are loaded into the polymers. After drying to remove the solvent, the resulting polymer contains a stabilized form of the SNAP or analog of SNAP. As an initial example, commercial silicone Foley catheters (i.d. of 0.30 cm and o.d. of 0.59 cm) were swelled in a SNAP solution prepared in tetrahydrofuran (THF) (125 mg mL^{-1}) for 24 h, resulting in SNAP impregnation of $5.43 \pm 0.15 \text{ wt}\%$ SNAP in the final dried catheter. This level of SNAP loading enabled the catheters to achieve stable NO release above physiological levels for >4 weeks.¹⁹

Catalysis-based NO generating polymers

Instead of incorporating NO donors or NO functionalities into polymers, many efforts have been devoted to generate NO from endogenous RNSOs or infusion of RSNO solutions through thiol transnitrosations,^{161,254} and subsequent catalytic reactions using immobilized copper or selenium-based species (e.g., copper nanoparticles,²⁵⁵ copper(II)-cyclen,^{171,256} copper-complexes,^{257,258} copper-containing metal-organic frameworks (MOFs),^{210–213} and organoselenium species^{115,172–174}). Meyerhoff and coworkers were the first to covalently attach copper(II)-cyclen onto commercial biomedical grade polyurethane, which can generate physiological levels of NO ($1\text{--}2 \times 10^{-10} \text{ mol cm}^{-2} \text{ min}^{-1}$) when in contact with endogenous RSNO and RSH species, such as 10 μM GSNO/GSH in PBS buffer containing 3 μM EDTA.¹⁷¹ This polymer has also been used as an outer coating at the distal end of an amperometric NO sensor that can generate electrochemical response toward the RSNO species in whole blood.¹⁷¹ However, it was reported that 50% of copper(II) ion leached out after soaking in GSNO/

GSH containing PBS buffer at RT for 7 d, which may limit the use of such polymers for long-term applications and generate cytotoxicity concerns.

Reynolds and coworkers are developing many MOF-NO generating catalysts with accessible catalytic sites and that have resistance to degradation, including $\text{Cu}_3(\text{BTC})_2$ (BTC: 1,3,5-benzenetricarboxylate), $\text{Cu}(\text{II})1,3,5\text{-benzene-tris-triazole}$ (CuBTri) and $\text{Cu}(\text{II})1,3,5\text{-tricarboxylate}$ (CuBTC).^{211–213} It has been reported that CuBTC can be extruded within Tecoflex SG80A polyurethane into single lumen tubing while maintaining the catalyst structure and functionality. The *in vitro* NO release generated from endogenous RSNO species ranges from 1 h to 16 h with tunable dosage, depending on the specific RSNO levels present in the soaking solution.²¹¹

As previously mentioned, Meyerhoff and coworkers have also demonstrated an electrochemical NO generation *via* a Cu^+ ion mediated reduction reaction of inorganic nitrite. The Cu^+ ion is generated from oxidation of a copper wire^{146,147} or the reduction of copper(II)-tri(2-pyridylmethyl)amine (Cu(II)TPMA) complex.¹⁴⁸ The electrochemically generated NO can be modulated by changing the potentials applied to the electrodes and can achieve fluxes between 0.5 and $3.5 \times 10^{-10} \text{ mol cm}^{-2} \text{ min}^{-1}$ (for catheter applications), which is in the range of physiological relevant levels of NO released by the endothelial cells. This approach has been utilized to develop a new generation of multi-lumen catheters in which one lumen is dedicated to generating NO electrochemically to reduce thrombus and microbial biofilm formation on the surface of the catheters.^{148,259}

Applications of NO releasing/generating polymers for preparing antithrombotic and antibacterial biomedical devices

Inhibition of thrombosis formation

In a healthy vasculature, endothelial NOS (eNOS) in the endothelial cells that line the inner wall of blood vessels produce NO with a surface flux of $0.5\text{--}4.0 \times 10^{-10} \text{ mol cm}^{-2} \text{ min}^{-1}$ to prevent platelet activation and thereby control the balance between thrombosis and hemorrhage.¹²⁰ However, many procedures (such as placing stents, grafts, catheters, or other biomedical devices) disrupt the endothelial cells lining and destroy the delicate balance of vascular homeostasis.¹³³ The tissue factor release and protein absorption trigger the coagulation cascade and the lack of NO production leads to platelet activation, aggregation, and ultimately thrombus formation. Therefore, NO and its unique antiplatelet/antithrombotic activity represents a very promising approach to prevent thrombus associated complications in many biomedical applications.

Mowery *et al.* reported that PVC- or PU-based polymer films, prepared with NO releasing diazeniumdiolate functionality *via* either dispersion or covalent bonding of NO donors, can exhibit significant improvements in biocompatibility during *in vitro* platelet adhesion tests using platelet-rich

plasma (PRP).³⁴ Wu *et al.* prepared PVC films (with borate additives and di(2-ethylhexyl) ester (DOS)) mixed with 0.5, 1.0, 2.0, 4.0 wt% of diazeniumdiolate N,N' -dibutyl-1,6-hexanediamine (DBHD/ N_2O_2) to determine the effect on platelet adhesion at the surface of polymeric films with various NO flux levels.²⁶⁰ A lactate dehydrogenase (LDH) assay was used to determine the amount of platelets adhered onto the polymer surface. LDH, which is normally stored within intact platelet, is released into the bulk solution when the platelets are lysed by surfactant and is a very useful for indication of the amount of cells adhered.²⁶⁰ Fewer platelets adhered on the polymer surfaces with higher NO flux levels, and NO successfully reduced the amount of platelets adhered on the polymer surfaces from $14.0 \pm 2.1 \times 10^5$ cells per cm^{-2} on the controls to $2.96 \pm 0.18 \times 10^5$ cells per cm^{-2} on the surfaces with highest NO release of $7.05 \times 10^{-10} \text{ mol cm}^{-2} \text{ min}^{-1}$.

Thrombosis is also an important risk factor in any blood exposure to synthetic materials, such as grafts, stents, intravascular sensors, catheters, extracorporeal circuits (ECC) or hemodialysis membranes.^{120,121,261,262} Efforts to use NO release polymers for these applications are summarized below based on the type of biomedical device.

Intravascular grafts. Keefer and coworkers were the first to test the antithrombotic and antiplatelet activity of NO released from a polymer matrix in animal models.²⁴⁰ Diazeniumdiolate cross-linked PEI coated PTFE vascular grafts were inserted into silicone rubber shunts that were placed between baboons' femoral and artery veins for 1 h. The autologous baboon platelets were labeled with indium-111-oxine before the start of experiment. The number of platelets adhered on the graft surface at the end of experiment was accessed by measuring the radioactivity intensity using a gamma scintillation camera. The NO-releasing grafts were found to be substantially less thrombogenic than the controls, suggesting considerable promise for this approach to improve the performance of vascular graft after implantation.²⁴⁰ The West¹¹⁶ and Wang¹¹⁵ groups both reported that NO releasing/generating grafts encourage endothelialization/endothelial cell proliferation, which can alleviate the complications of thrombosis and intimal hyperplasia (IH) that cause the failure of small diameter vascular grafts without the use of systemic anticoagulants.

Intravascular sensors. Monitoring the levels of chemical species in blood (such as blood gases (PO_2 , pH, and PCO_2), electrolytes (K^+ , Na^+ , Ca^{2+}), glucose, lactate, *etc.*) can provide invaluable information for diagnosis and treatment of hospitalized patients.²⁶³ Currently, however, measurements are done *in vitro* with point-of-care devices intermittently, leaving large gaps of information between blood draws.^{259,264} Therefore, developing intravascular sensors that can monitor key chemical species in real time in critically ill patients is an important avenue of research.²⁶⁵ However, adhesion of platelets, and eventual thrombus formation on the surface of the sensors can occur within a few hours after blood contact, and such processes can not only isolate the chemical sensing area from the bulk of the blood and lead to false analytical results

but also increase the risk of emboli or stroke.^{8,266} Many researchers have attempted to address this problem by incorporating continuous NO release/generation into the sensor design to prevent adhesion of metabolically active platelets from adhering to the sensor surface. To increase the biocompatibility of intravascular oxygen sensors, Marxer *et al.* developed an amperometric sol-gel derived oxygen sensor that consists of a platinum electrode coated with a diazeniumdiolate and polyurethane containing xerogel film.²⁶⁷ The coating released NO at a flux up to $4.32 \times 10^{-10} \text{ mol cm}^{-2} \text{ min}^{-1}$ for the first 12 h and effectively reduced platelet adhesion in the *in vitro* biocompatibility testing when immersed in platelet rich plasma for 1 h at 37 °C. Instead of directly coating the electrodes with NO release polymers, many catheter-style intravascular oxygen sensors have been developed for testing *in vivo* with NO released or generated through the polymeric material of the catheters. So far, several different NO delivery approaches have been reported for such intravascular oxygen sensors, including coating the catheter surface with NONOates,^{268,269} covalently attaching NONOates to catheter polymer surface,²⁷⁰ catalytically generating NO *in situ* from endogenous RSNOs using embedded copper particles^{8,271} and electrochemically modulating NO generation from nitrite.²⁵⁹ For example, Schoenfisch *et al.* coated outer surfaces of SR catheters with 2 wt% (Z)-1-[N-methyl-N-[6-(N-methylammoniohexyl)amino]] diazeniumdiolate (MAHMA/N₂O₂) and demonstrated that the NO release from the catheter lasted more than 20 h in PBS at 37 °C. One control (coated only with MAHMA) and one NO release catheter (coated with MAHMA/N₂O₂) were implanted within the carotid or left femoral arteries in a canine model for 12–23 h. The electrochemical response of the NO-releasing O₂ sensor more closely represented the real arterial blood gas value measured by a benchtop blood-gas analyzer than the control sensor, which had a significant discrepancy starting from the first few hours after the implantation. SEM images also confirmed that a much greater number of platelets adhered and aggregated on the surfaces of the control sensors compared to the NO releasing sensors. In a separate study, Ren *et al.* recently demonstrated the use of a dual lumen catheter configuration to combine an amperometric oxygen sensor (in one lumen) with the electrochemical NO generation in the other lumen using Cu(II)TPMA as the mediator for reduction of nitrite ions to NO²⁵⁹ (see Fig. 8).

Applying different potentials on the electrodes can modulate the rate of NO generation, which offers a steady, controllable, and physiologically relevant flux of NO, compared to the chemically-based NO generation. The performance of the sensor was evaluated in rabbit veins and pig arteries for 7 and 21 h, respectively. The sensors in the arteries were challenged with a wider range of oxygen levels by changing the pig's fraction of inspired oxygen between 100% and 21%.²⁵⁹ In both cases, the sensors with electrochemical NO generation provided very accurate oxygen responses, while control sensors deviated from the real values by 30–40% after 5 h of implantation because the local oxygen was consumed by the activated platelets and other cells trapped in the thrombus formed on




Fig. 8 Simplified schematic of dual-lumen catheter-type oxygen sensor with electrochemical NO generation from nitrite solution via Cu(II)TPMA (figure not drawn to scale).

the surface of the control sensors. Similar to oxygen sensors, NO releasing intravascular glucose,^{272–276} pH,^{276,277} and CO₂^{276,278} sensors using diazeniumdiolated NO donors have also been tested, demonstrating much improved electrochemical responses over the corresponding control sensors.

Extracorporeal circulations (ECCs). Extracorporeal circuits are used for several different types of medical procedures, such as hemodialysis, cardiac bypass surgery, and extracorporeal membrane oxygenation (ECMO). The latter is employed to keep newborn babies alive for weeks at a time, if their lungs are not fully developed. The need for systemic anticoagulation in each of these extracorporeal procedures can be problematic, particularly in patients that have heparin induced thrombocytopenia (HIT). Due to the large surface area that is in contact with blood in extracorporeal circulation (ECC), the loss of platelet count and platelet functionality are significant,¹⁶² and many researchers have developed NO releasing^{43,155,156,162,237,239,279,280} or NO generating²⁵⁵ polymeric ECC tubing to prevent platelet activation and consumption during this process (see Table 1).

Zhang *et al.* prepared PVC tubing with PU coating containing 20 wt% diazeniumdiolated FS particle fillers²³⁷ and SR tubing with covalently attached to DACA/N₂O₂²³⁹ as NO releasing polymer tubing circuits for 4 h ECC experiments in a rabbit model. Both types of NO release tubing exhibited less overall platelet adhesion and thrombus surface coverage compared to the controls. However, it still remains a challenge to achieve long-term NO release at physiologically relevant conditions, stable storage capability at room temperatures and high NO donor loading. Handa *et al.* recently prepared ECC tubing composed of 25 wt% DBHD/N₂O₂ and 10 wt% PLGA (5050DLG7E) additives in 2:1 PVC/DOS polymer matrix and achieved up to 14 d of NO release between $7–18 \times 10^{-10} \text{ mol cm}^{-2} \text{ min}^{-1}$ at 37 °C.¹⁵⁵ This circuit tubing successfully pre-

Table 1 Summary of NO releasing and NO generating coatings reported to increase the hemocompatibility of extracorporeal circuits (ECC)

Summary	ECC coating material	NO donor, additives, etc.	NO level ($\times 10^{-10}$ mol min ⁻¹ cm ²)	Platelet count after 4 h (% of initial)	Ref	
NO release	Covalent attachment	Tygon tubings with Carbonthane 3573A coating	<i>N</i> -Diazeniumdiolated FS fillers	4.1	<i>ca.</i> 85 \pm 15% (NO) <i>vs.</i> 58 \pm 5% (PU)	237
		Silicone rubber tubings	<i>N</i> -Diazeniumdiolated PDMS	>4.0 at 23 °C; >10.0 at 37 °C	86 \pm 24% (NO) <i>vs.</i> 65 \pm 10% (SR)	239
	Physical dispersion	Tygon tubings with PVC/DOS coating	DBHD/NONOate, borate	12.5	79 \pm 7% (NO) <i>vs.</i> 58 \pm 7% (PVC/DOS)	279
		Tygon tubings with PVC/DOS coating	DBHD/NONOate, PLGA	>20	79 \pm 11% (NO) <i>vs.</i> 54 \pm 6% (PVC/DOS)	155
		Tygon tubings with Elasteon-E2As coating	DBHD/NONOate, PLGA	6	97 \pm 10% (NO) <i>vs.</i> 58 \pm 3% (E2As)	156
		Tygon tubings with Elasteon-E2As coating	DBHD/NONOate, PLGA, argatroban	6.5	<i>ca.</i> 90% (NO/argatroban) <i>vs.</i> 58 \pm 3% (E2As)	43
NO generation	Tygon tubings with Elasteon-E2As coating	SNAP	2	100 \pm 7% (NO) <i>vs.</i> 60 \pm 6% (E2As)	162	
	Tygon tubings with Tecophilic SP-60D-60 coating containing 10 wt% Cu ⁰ nanoparticle	Endogenous RSNO and/or infused SNAP	>10 (in presence of 1 μ M GSNO, 30 μ M GSH, 5 μ M EDTA)	<i>ca.</i> 90% (10 wt% Cu ⁰ and SNAP) <i>vs.</i> 75% (10 wt% Cu ⁰ only) <i>vs.</i> 50% (SNAP only)	255	
Inherent polymer properties	Tygon tubings with Tecoflex SG 80A, Tecophilic SP-60D-60, PVC/DOS coating	N/A	N/A	44 \pm 4% (SG 80A) <i>vs.</i> 41 \pm 5% (SP-60D-60) <i>vs.</i> 46 \pm 3% (PVC/DOS)	156	

served the platelet count during 4 h of experiments, with 79 \pm 11% *vs.* 54 \pm 6% for the NO release circuits compared to PVC/DOS controls. In a subsequent study by the same authors, four different biomedical grade polymers were evaluated for their inherent hemocompatibility in 4 h ECC experiments in rabbits.¹⁵⁶ The type of polymer material can ultimately influence their efficiency as NO releasing coatings. E2As polymer was found to be the most biocompatible material amongst the four tested. E2As coated ECC tubing can preserve 56% of baseline platelet after 4 h *versus* 48, 40 and 47% for PVC/DOS, Tecophilic SP-60D-60 and Tecoflex SG 80A, respectively. Major *et al.* later used E2As polyurethane with DBHD/N₂O₂ and a direct thrombin inhibitor argatroban (AG) as an ECC coating to better mimic the vascular endothelium. The results showed that the combined AG/DBHD polymer coatings can better prevent thrombus formation after 4 h of blood exposure compared to control ECCs or ECCs with coatings containing only DBHD/N₂O₂ or AG alone.⁴³

In addition to diazeniumdiolates, RSNOs has also been used to create NO releasing coatings for ECC applications. Brisbois *et al.*¹⁶² were the first to discover that SNAP-doped E2As polymer films exhibit unprecedented shelf-life stability, with 82% of the initial SNAP remaining after 2 months storage at 37 °C. The 10 wt% SNAP/E2As films can release NO for up to 20 d at levels above the physiological NO flux range. In the ECC experiments with rabbits, the inner walls of PVC ECC circuits were coated with the SNAP/E2As polymer. Such coated tubing successfully preserved the platelet count during the 4 h of experiments (at 100 \pm 7% *vs.* 60 \pm 6% for controls), with 33% less thrombus formation on the tubings' inner surfaces.

Another related approach to increase the biocompatibility of ECC tubing is to generate NO catalytically using infused

RSNOs.²⁵⁵ Hydrophilic SP-60D-60 polyurethane polymer containing 10 wt% Cu⁰ nanoparticles (NP) (80 nm) coated on the inner walls of ECC circuit tubing were tested in the rabbit thrombogenicity model. Experiments were conducted with and without intravenous SNAP infusion (0.1182 μ mol kg⁻¹ min⁻¹) over a 4 h period. The Cu⁰ NP embedded ECC circuit with SNAP infusion yields considerably less thrombus (0.4 \pm 0.2 pixels per cm²) on the surface of the chamber after 4 h, as compared to the Cu⁰ NP circuit without SNAP infusion (3.2 \pm 0.2 pixels per cm²) or the control circuit without Cu⁰ NP (4.9 \pm 0.5 pixels per cm²). Of note, since the endogenous RSNO levels are low (*e.g.*, 1–10 μ mol L⁻¹ for SNO-albumin),²⁸¹ this approach requires consistent supply of infused RSNOs to provide continuous catalytic generation of NO at the flowing blood/polymer tubing interface.²⁵⁵

Prevention bacterial infection or biofilm formation

Nitric oxide (NO) has antimicrobial activity against a growing list of microorganisms, including bacteria, fungi, parasites, viruses, and yeast.^{20,112,121,128,178,282,283} However, for medical device applications, the focus has thus far been on its antibacterial/antibiofilm properties, especially for the bacteria that most commonly cause CRBSIs (catheter related bloodstream infections), such as *Staphylococcus epidermidis* (*S. epidermidis*), *Staphylococcus aureus* (*S. aureus*), and *Pseudomonas aeruginosa* (*P. aeruginosa*).^{66,104} It has been clearly demonstrated that NO releasing/generating polymers can have strong bactericidal effects,^{19,147,148,163,202,228,284,285} even for bacteria that are able to metabolize and deactivate NO, such as *P. aeruginosa*, that possesses NO reductase enzyme that converts NO to nitrous oxide (N₂O) and ultimately nitrogen (N₂).^{87,202,220} Of note, NO

possesses broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA).^{220,282} Moreover, the dose of NO required to kill bacteria (e.g., 200 ppm of gaseous NO)^{282,283,286} does not show any cytotoxic effects in human dermal fibroblasts when exposed for 48 h.^{217,221} In addition to its bactericidal activity at high dosage, low levels of NO (picomolar to nanomolar range in solution phase)²⁸⁷ also serve as a key mediator that minimize planktonic bacteria adhesion and colonization, as well as disperse mature biofilm and release the bacteria trapped in the EPS film back to their planktonic state.^{287–289} It has been proposed that exposure to low doses of NO restore the sensitivity of biofilm and dispersed bacteria towards several types of antibiotics, greatly increasing their efficacy.²⁸⁷ Overcoming bacteria colonization on the surfaces of biomedical devices through continuous NO release represents an innovative and highly desirable approach to reduce risk of infections, which can ultimately increase device functionality and success rates, reduce morbidity and mortality, and improve patient outcomes.

Frost *et al.* successfully develop a *S*-nitroso-*N*-acetyl-D-penicillamine functionalized polymer matrix (e.g., PDMS,²²⁷ cyclam²⁴⁴ and gelatin²²³) that can release NO *via* light-initiated SNAP decomposition. SNAP modified purified gelatin can release NO up to $1 \times 10^{-8} \mu\text{mol mg}^{-1} \text{s}^{-1}$ under a 527 nm wavelength light-emitting diode (LED) and it also shows continuous and light intensity-responsive NO release over 24 h, with a total payload of $0.06 \mu\text{mol NO mg}^{-1}$.²²³ The antibacterial activity of SNAP/gelatin was tested against *S. aureus* (3×10^5 CFU mL⁻¹) and it demonstrated the ability to create a zone of inhibition of 1.2 ± 0.7 mm and 0.75 ± 0.3 mm, when exposed to the 4.5 V and 3 V LED light, respectively, over 24 h. Schoenfisch and coworkers have evaluated the antibacterial characteristics of NO releasing sol-gel coatings²⁹⁰ and xerogel films²¹⁷ which are capable of releasing NO for 5 and 14 d, respectively, against a 10^8 colony forming units (CFU) per mL saline suspension of *P. aeruginosa* for up to 4 h. NO successfully reduced bacterial cell coverage on these surfaces by up to 40%. Recently, Reynolds and coworkers developed a water-soluble NO-releasing polysaccharide derivative that can release 100% of its NO storage capacity ($49.5 \pm 5.0 \mu\text{mol g}^{-1}$) over 24 h.²²⁸ The bactericidal activity of this species was evaluated against *E. coli*, *Acinetobacter baumannii* (*A. baumannii*) and *S. aureus* and the reported data demonstrated an 8-log unit reduction in viable bacteria cell counts for all three types of bacteria after 24 h of incubation. The absence of CFU counts after 72 h corroborated that there was no bacterial growth recovery after exposure to NO. This is the first time a water-soluble antibacterial agent has reached an industrially relevant level of antimicrobial activity.²²⁸

Further, it is also well known that bacteria in mature biofilms are much harder to eradicate than when they are in planktonic stage. Meyerhoff and coworkers have conducted many experiments where the antibacterial properties of NO releasing polymer were evaluated against mature biofilm, developed in CDC bioreactors prior to contacting with NO.^{146,148}

Electrochemical NO generating catheters using inner copper wire working electrode and inorganic nitrite salt solution can generate NO through the walls of the catheters with a flux $>1.0 \times 10^{-10} \text{ mol cm}^{-2} \text{ min}^{-1}$ for more than 60 h.¹⁴⁷ First, the catheters were mounted in a drip-flow bioreactor, which is a standardized model that allows growth of high biomass-biofilm of *E. coli* at the air liquid interface when incubated with in LB (Luria Bertani) broth for 2 d and 4 d without the NO turned on. After allowing biofilm to form on catheter surfaces, the electrochemical NO release was “turned on” for only 3 h at the end of the experiments. The short period of NO release was effective at dispersing and killing the *E. coli* biofilm, and could lower the number of live bacteria adhered on the catheter surfaces by $>99.9\%$. In a separate study, Backlund *et al.*²¹⁵ synthesized diazeniumdiolated PAMAM dendrimers with different alkyl chain modifications and examined their antibacterial properties against 24 h old *Streptococcus mutans* biofilm (*S. mutans*) at pH 7.4 and 6.4. The bactericidal action of the NO releasing dendrimers was reported to increase with alkyl chain length of the dendrimer and lower pH. In another experiment conducted by Schoenfisch and coworkers, a Center for Disease Control (CDC) bioreactor, that mimics bacterial growth under different shear force conditions, was used to grow *P. aeruginosa* biofilms over a 48 h period. The biofilms were then exposed to a water-soluble NO releasing chitosan oligosaccharide ($0.17\text{--}0.46 \mu\text{mol NO mL}^{-1}$) for 24 h. The presence of the NO release elicited a 5-log unit reduction in viable bacterial counts with a minimal bactericidal concentration (MBC) of the dendrimer preparation as low as $400 \mu\text{g mL}^{-1}$.²²¹

Continuous NO release during bacterial proliferation has also been proven to prevent biofilm formation. Cai *et al.* fabricated NO releasing silicone rubber films containing DBHD/ N_2O_2 along with PLGA (RG 502H) additives that can release NO for 10 d at physiological conditions. pH sensitive dyes were incorporated in the films to help visualize the pH change within the polymeric matrix due to slow hydrolysis of the PLGA that promotes the extended NO release.¹⁵⁷ Both the NO release and control films were incubated in a CDC bioreactor for 7 d at 37 °C and the number of live bacteria on the surfaces of the silicone rubber was assessed. The NO release films exhibited substantial antibiofilm properties against both Gram-positive *S. aureus* (98.4% reduction) and Gram-negative *E. coli* (99.9% reduction) when compared to controls.¹⁵⁷ In subsequent studies, Colletta *et al.*¹⁹ and Ketchum *et al.*¹⁹⁰ used the solvent impregnation method previously described above (see section Physical Encapsulation-based NO Releasing Polymers) to load silicone-based tubing with NO donors (SNAP and lipophilic SNAP derivatives, respectively) and demonstrated that they have antibacterial effects toward several microorganisms (e.g., *Staphylococcus epidermis*, *Proteus mirabilis* or *S. aureus*). These results offer a new strategy to reduce bacterial infections associated with not only intravascular catheters but also urinary catheters.

In addition to *in vitro* experiments, NO releasing polymers (e.g., catheters) have also exhibited both antithrombotic and antibacterial properties *in vivo*. Brisbois *et al.* conducted

experiments where both SNAP-doped E2As catheter and control E2As catheters were implanted in sheep jugular veins for 7 d.¹⁸⁷ At the end of the 7 d period, the catheters were carefully explanted and both the clot area as well as the number of live bacteria adhered on the catheter surfaces were assessed. The 10 wt% SNAP/E2As catheters exhibited enhanced hemocompatibility (70% less thrombus formation) and bactericidal activity (90% reduction of bacteria adhesion) when compared to the controls.

Nitric oxide releasing polymers have also provided a potential strategy for use as active wound healing dressings, capable of reducing bacterial infections at wound sites and accelerating the wound healing process for incisional and excisional wounds,^{180,220,222} burn wounds,²⁹¹ and diabetic wounds.²³³ While normal fibroblasts do not synthesize NO, it has been demonstrated that fibroblasts isolated from the regular wound can release NO.²⁹² The iNOS is synthesized in the early phase of wound healing by inflammatory cells, such as macrophages, monocytes, and other immune lineage cells.^{120,121,293} The NO released through iNOS enhances angiogenesis, regulates collagen formation, cell proliferation and wound contractions.^{112,293} Studies using induced NOS (iNOS) knock out mice showed diminished collagen deposition, with the restoration of normal collagen deposits upon exposure to SNAP, indicating the important relationship between NO production and wound healing.²⁹⁴ Therefore, elevating the local NO concentration at a wound site by an exogenous NO supply represents a promising strategy to facilitate the wound healing process.

Yoo and coworkers developed PEI/NONOate nanoparticles (NPs) capable of prolonged NO release, which were then used to treat MRSA-infected excisional wounds (5 mm diameter, full thickness) in mice.²²⁰ MRSA was inoculated in the wound for 1 d to develop infection and then the wounds were treated with the NO releasing NPs or control NPs over 6 d. The photographs of the wounds taken at day 0, 1, 4 and 7 clearly showed an accelerated wound healing process for mice treated with NPs, with wound area reduced to 25% at the end of 7 d. The untreated wounds showed a thicker scab with no reduction in the wound area. In a subsequent study, GSNO-doped chitosan films, which exert strong antimicrobial activity against a broad spectrum of bacteria, were evaluated as a wound healing dressing on full thickness excisional wounds (1.5 cm × 1.5 cm) in a rat model for 15 d.²²² Comparing the NO-treated and untreated wounds, those treated with the GSNO/Chitosan dressing were almost completely healed at the end of the 15 d, with less bacterial burden and decreased inflammatory cell infiltration, but enhanced re-epithelialization.^{121,222} Brisbois *et al.* tested the antibacterial efficacy of DBHD/N₂O₂ and PLGA (5050DLG1A) doped biomedical grade PU films as a dressing for burn wounds (10 cm² and partial thickness) in a mouse model.²⁹¹ Burn wounds are quite common, but difficult to treat and often lead to infections.¹¹² The burn wounds in mice were inoculated by *A. baumannii* for 24 h prior to application of the NO and control wound dressings. After 24 h of treatment, the wound area skin tissue was harvested and assessed for number of viable bacteria adhered at the wound sites. A 4-log

unit bacterial reduction was observed for the NO treated wounds when compared to the control wound sites.

Conclusions

As detailed above, there are many approaches that have been examined to improve the biocompatibility and antimicrobial activity of biomedical polymers/devices. Most of the conventional approaches, (*e.g.*, creating heparin-releasing surfaces, bacteria-resistant or biocide-releasing surfaces, *etc.*), can only improve either the hemocompatibility or the antibacterial properties of the devices. However, NO release or generating polymers have demonstrated very positive effects in terms of preventing both platelet activation and thrombus formation as well as exhibiting significant antimicrobial activity toward infection/biofilm formation without bacterial resistance. Although this review mainly focused on the use of NO release polymers for antithrombotic and antibacterial applications, these polymers also have many other potential applications for use on skin, bones, connective tissue, gastroenterology, or studying NO-induced cellular responses.^{112,178,295,296}

Recently, considerable effort has been devoted to develop combination therapy and hybrid drugs that combine NO release functionality with other active agents for increased efficacies, including anticoagulants,^{35,127} direct thrombin inhibitors,^{36,43} antimicrobial metal ions,²¹⁶ quaternary ammonium compounds,⁷¹ PEG,¹¹⁶ antibiotics,²⁹⁷ and non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen.¹⁴¹ The remaining challenge for NO delivery polymers in order to be used in clinical settings lies in the development of more stable NO donors and polymer scaffolds and delivering the desired amount NO in a controlled spatial and temporal manner. In many cases, long-term NO release is desired, especially for using NO-releasing, blood compatible polymeric materials for preparing intravascular grafts, stents, catheters, and other vascular access devices. Further research should focus on the dose-dependent biological responses to different NO concentrations and aim towards developing clinically relevant NO delivery materials for that purpose, that can ultimately expedite the translation of these materials from the laboratory to clinical use. Overall, both *in vitro* and *in vivo* (animals) studies of some of the NO releasing/generating polymers developed to date have clearly demonstrated the immense potential of this approach to improve the hemocompatibility/antimicrobial activity of a variety of biomedical devices that are required to improve patient care. Hopefully, the first commercial devices that employ this strategy will soon become available for routine use within hospitals.

Acknowledgements

We thank the National Institutes of Health (grants HL-128337 and HL-119403) for funding research in our laboratory on the development of novel NO release biomedical polymers/devices.

References

- 1 N. Naghavi, A. De Mel, O. S. Alavijeh, B. G. Cousins and A. M. Seifalian, *Small*, 2013, **9**, 22–35.
- 2 M. B. Gorbet and M. V. Sefton, *Biomaterials*, 2004, **25**, 5681–5703.
- 3 E. J. Brisbois, H. Handa and M. E. Meyerhoff, in *Advanced Polymers in Medicine*, ed. F. Puoci, Springer International Publishing, Cham, 2015, pp. 481–511.
- 4 M. V. Sefton, C. H. Gemmell and M. B. Gorbet, *J. Biomater. Sci., Polym. Ed.*, 2000, **11**, 1165–1182.
- 5 M. B. Gorbet and M. V. Sefton, in *The Biomaterials: Silver Jubilee Compendium*, Elsevier, 2004, vol. 25, pp. 219–241.
- 6 T. A. Horbett, *Cardiovasc. Pathol.*, 1993, **2**, 137–148.
- 7 J. D. Andrade and V. Hlady, in *Advances in Polymer Science*, 1986, vol. 79, pp. 1–63.
- 8 Y. Wu and M. E. Meyerhoff, *Talanta*, 2008, **75**, 642–650.
- 9 R. M. Klevens, J. R. Edwards, C. L. Richards, T. C. Horan, R. P. Gaynes, D. A. Pollock and D. M. Cardo, *Public Health Rep.*, 2007, **122**, 160–166.
- 10 C. Abad and N. Safdar, *Infect. Dis. Spec. Ed.*, 2011.
- 11 H. Shah, W. Bosch, K. M. Thompson and W. C. Hellinger, *Neurohospitalist*, 2013, **3**, 144–151.
- 12 L. A. Mermel, M. Allon, E. Bouza, D. E. Craven, P. Flynn, N. P. O'Grady, I. I. Raad, B. J. Rijnders, R. J. Sherertz and D. K. Warren, *Clin. Infect. Dis.*, 2009, **49**, 1–45.
- 13 A. Sitges-Serra and M. Girvent, *World J. Surg.*, 1999, **23**, 589–595.
- 14 M. R. Goede and C. M. Coopersmith, *Surg. Clin. North Am.*, 2009, **89**, 463–474.
- 15 R. Gahlot, C. Nigam, V. Kumar, G. Yadav and S. Anupurba, *Int. J. Crit. Illn. Inj. Sci.*, 2014, **4**, 162–167.
- 16 M. Chen, Q. Yu and H. Sun, *Int. J. Mol. Sci.*, 2013, **14**, 18488–18501.
- 17 R. M. Donlan, *Clin. Infect. Dis.*, 2001, **33**, 1387–1392.
- 18 J. B. Kaplan, *J. Dent. Res.*, 2010, **89**, 205–218.
- 19 A. Colletta, J. Wu, Y. Wo, M. Kappler, H. Chen, C. Xi and M. E. Meyerhoff, *ACS Biomater. Sci. Eng.*, 2015, **1**, 416–424.
- 20 E. M. Hetrick and M. H. Schoenfisch, *Chem. Soc. Rev.*, 2006, **35**, 780–789.
- 21 J. Hirsh, *N. Engl. J. Med.*, 1991, **324**, 1565–1574.
- 22 A. Gutowska, Y. H. Bae, H. Jacobs, F. Mohammad, D. Mix, J. Feijen and S. W. Kim, *J. Biomed. Mater. Res.*, 1995, **29**, 811–821.
- 23 T. E. Warkentin, C. P. Hayward, C. A. Smith, P. M. Kelly and J. G. Kelton, *J. Lab. Clin. Med.*, 1992, **120**, 371–379.
- 24 H. Tanzawa, Y. Mori, N. Harumiya, H. Miyama, M. Hori, N. Ohshima and Y. Idezuki, *ASAIO J.*, 1973, **19**, 188–194.
- 25 V. L. Gott, J. D. Whiffen and R. C. Dutton, *Science*, 1963, **142**, 1297–1298.
- 26 R. Shibuta, M. Tanaka, M. Sisido and Y. Imanishi, *J. Biomed. Mater. Res.*, 1986, **20**, 971–987.
- 27 C. A. Hufnagel, P. W. Conrad, J. F. Gillespie, R. Pifarre, A. Llano and T. Yokoyama, *Ann. N. Y. Acad. Sci.*, 1968, **146**, 262–270.
- 28 J. Y. Lin, C. Nojiri, T. Okano and S. W. Kim, *ASAIO Trans.*, 1987, **33**, 602–605.
- 29 P. W. Heyman, C. S. Cho, J. C. McRea, D. B. Olsen and S. W. Kim, *J. Biomed. Mater. Res.*, 1985, **19**, 419–436.
- 30 C. Ebert, J. McRea and S. W. Kim, in *Controlled Release of Bioactive Materials*, Elsevier, 1980, pp. 107–122.
- 31 A. Gutowska, Y. H. Bae, J. Feijen and S. W. Kim, *J. Controlled Release*, 1992, **22**, 95–105.
- 32 S. Wan Kim and H. Jacobs, *Blood Purif.*, 1996, **14**, 357–372.
- 33 N. Ayres, D. J. Holt, C. F. Jones, L. E. Corum and D. W. Grainger, *J. Polym. Sci., Part A: Polym. Chem.*, 2008, **46**, 7713–7724.
- 34 K. A. Mowery, M. H. Schoenfisch, J. E. Saavedra, L. K. Keefer and M. E. Meyerhoff, *Polymer*, 2000, **21**, 9–21.
- 35 Z. Zhou and M. E. Meyerhoff, *Biomaterials*, 2005, **26**, 6506–6517.
- 36 B. Wu, B. Gerlitz, B. W. Grinnell and M. E. Meyerhoff, *Biomaterials*, 2007, **28**, 4047–4055.
- 37 S. E. Sakiyama-Elbert, *Acta Biomater.*, 2014, **10**, 1581–1587.
- 38 P. C. Begovac, R. C. Thomson, J. L. Fisher, A. Hughson and A. Gallhagen, *Eur. J. Vasc. Endovasc. Surg.*, 2003, **25**, 432–437.
- 39 C. Devine and C. McCollum, *J. Vasc. Surg.*, 2004, **40**, 924–931.
- 40 P. Olsson, J. Sanchez, T. E. Mollnes and J. Riesenfeld, *J. Biomater. Sci., Polym. Ed.*, 2000, **11**, 1261–1273.
- 41 A. G. Kidane, H. Salacinski, A. Tiwari, K. R. Bruckdorfer and A. M. Seifalian, *Biomacromolecules*, 2004, **5**, 798–813.
- 42 S. W. Jordan and E. L. Chaikof, *J. Vasc. Surg.*, 2007, **45**, 104–115.
- 43 T. C. Major, E. J. Brisbois, A. M. Jones, M. E. Zanetti, G. M. Annich, R. H. Bartlett and H. Handa, *Biomaterials*, 2014, **35**, 7271–7285.
- 44 N. A. Peppas, Y. Huang, M. Torres-Lugo, J. H. Ward and J. Zhang, *Annu. Rev. Biomed. Eng.*, 2000, **2**, 9–29.
- 45 O. Wichterle and D. Lim, *Nature*, 1960, **185**, 117–118.
- 46 S. Lakshmi and A. Jayakrishnan, *Artif. Organs*, 1998, **22**, 222–229.
- 47 B. Balakrishnan, D. S. Kumar, Y. Yoshida and A. Jayakrishnan, *Biomaterials*, 2005, **26**, 3495–3502.
- 48 C. R. Blass, C. Jones and J. M. Courtney, *Int. J. Artif. Organs*, 1992, **15**, 200–203.
- 49 G. R. Llanos and M. V. Sefton, *J. Biomed. Mater. Res.*, 1993, **27**, 1383–1391.
- 50 J. M. Harris, *Poly(Ethylene Glycol) Chemistry*, Springer US, Boston, MA, Netherlands, 1992, vol. 11.
- 51 M. C. Tanzi, *Expert Rev. Med. Devices*, 2005, **2**, 473–492.
- 52 S. K. Williams, D. G. Rose and B. E. Jarrell, *J. Biomed. Mater. Res.*, 1994, **28**, 203–212.
- 53 P. Zilla, M. Deutsch, J. Meinhart, R. Puschmann, T. Eberl, E. Minar, R. Dudczak, H. Lugmaier, P. Schmidt and I. Noszian, *J. Vasc. Surg.*, 1994, **19**, 540–548.
- 54 S. R. Shah, A. M. Tataru, R. N. D'Souza, A. G. Mikos and F. K. Kasper, *Mater. Today*, 2013, **16**, 177–182.
- 55 S.-H. Park, S. Lee, D. Moreira, P. R. Bandaru, I. Han and D.-J. Yun, *Sci. Rep.*, 2015, **5**, 15430.

- 56 W. Ye, Q. Shi, J. Hou, J. Jin, Q. Fan, S.-C. Wong, X. Xu and J. Yin, *J. Mater. Chem. B*, 2014, **2**, 7186–7191.
- 57 X. Gao and L. Jiang, *Nature*, 2004, **432**, 36.
- 58 U. Nydegger, R. Rieben and B. Lämmle, *Transfus. Sci.*, 1996, **17**, 481–488.
- 59 G. Cheng, H. Xue, Z. Zhang, S. Chen and S. Jiang, *Angew. Chem., Int. Ed.*, 2008, **47**, 8831–8834.
- 60 E. Ostuni, R. G. Chapman, R. E. Holmlin, S. Takayama and G. M. Whitesides, *Langmuir*, 2001, **17**, 5605–5620.
- 61 S.-H. Hsu, Y.-C. Kao and Z.-C. Lin, *Macromol. Biosci.*, 2004, **4**, 464–470.
- 62 S.-H. Hsu and Y.-C. Kao, *Macromol. Biosci.*, 2005, **5**, 246–253.
- 63 L.-C. Xu, P. Soman, J. Runt and C. A. Siedlecki, *J. Biomater. Sci., Polym. Ed.*, 2007, **18**, 353–368.
- 64 Q. Yu, Z. Wu and H. Chen, *Acta Biomater.*, 2015, **16**, 1–13.
- 65 I. Kolodkin-Gal, D. Romero, S. Cao, J. Clardy, R. Kolter and R. Losick, *Science*, 2010, **328**, 627–629.
- 66 M. R. Kiedrowski and A. R. Horswill, *Ann. N. Y. Acad. Sci.*, 2011, **1241**, 104–121.
- 67 S. Sepehr, A. Rahmani-Badi, H. Babaie-Naiej and M. R. Soudi, *PLoS One*, 2014, **9**.
- 68 J. A. Jennings, H. S. Courtney and W. O. Haggard, *Clin. Orthop. Relat. Res.*, 2012, **470**, 2663–2670.
- 69 M. C. Jennings, L. E. Ator, T. J. Paniak, K. P. C. Minbiole and W. M. Wuest, *ChemBioChem*, 2014, **15**, 2211–2215.
- 70 M. C. Jennings, K. P. C. Minbiole and W. M. Wuest, *ACS Infect. Dis.*, 2015, 288–303.
- 71 A. W. Carpenter, B. V. Worley, D. L. Slomberg and M. H. Schoenfish, *Biomacromolecules*, 2012, **13**, 3334–3342.
- 72 A. S. Abd-El-Aziz, C. Agatemor, N. Etkin, D. P. Overy, M. Lanteigne, K. McQuillan and R. G. Kerr, *Biomacromolecules*, 2015, **16**, 3694–3703.
- 73 N. D. Allan, K. Giare-Patel and M. E. Olson, *J. Biomed. Biotechnol.*, 2012, **2012**, 921617.
- 74 K. Wu, Y. Yang, Y. Zhang, J. Deng and C. Lin, *Int. J. Nanomed.*, 2015, **10**, 7241–7252.
- 75 L. Mei, Z. Lu, X. Zhang, C. Li and Y. Jia, *ACS Appl. Mater. Interfaces*, 2014, **6**, 15813–15821.
- 76 S. K. Sehmi, S. Noimark, J. Weiner, E. Allan, A. J. MacRobert and I. P. Parkin, *ACS Appl. Mater. Interfaces*, 2015, **7**, 22807–22813.
- 77 L. Zhang, C. Ning, T. Zhou, X. Liu, K. W. K. Yeung, T. Zhang, Z. Xu, X. Wang, S. Wu and P. K. Chu, *ACS Appl. Mater. Interfaces*, 2014, **6**, 17323–17345.
- 78 S. Rossi, A. O. Azghani and A. Omri, *J. Antimicrob. Chemother.*, 2004, **54**, 1013–1018.
- 79 L. Zhao, P. K. Chu, Y. Zhang and Z. Wu, *J. Biomed. Mater. Res., Part B*, 2009, **91**, 470–480.
- 80 R. Cademartiri, H. Anany, I. Gross, R. Bhayani, M. Griffiths and M. A. Brook, *Biomaterials*, 2010, **31**, 1904–1910.
- 81 U. Puapermpoonsiri, J. Spencer and C. F. van der Walle, *Eur. J. Pharm. Biopharm.*, 2009, **72**, 26–33.
- 82 T. Wei, Q. Yu, W. Zhan and H. Chen, *Adv. Healthcare Mater.*, 2016, **5**, 449–456.
- 83 G. Cado, R. Aslam, L. Séon, T. Garnier, R. Fabre, A. Parat, A. Chassepot, J.-C. Voegel, B. Senger, F. Schneider, Y. Frère, L. Jierry, P. Schaaf, H. Kerdjoudj, M.-H. Metz-Boutigue and F. Boulmedais, *Adv. Funct. Mater.*, 2013, **23**, 4801–4809.
- 84 K. V. Holmberg, M. Abdolhosseini, Y. Li, X. Chen, S.-U. Gorr and C. Aparicio, *Acta Biomater.*, 2013, **9**, 8224–8231.
- 85 J. Li, Z. Chen, M. Zhou, J. Jing, W. Li, Y. Wang, L. Wu, L. Wang, Y. Wang and M. Lee, *Angew. Chem., Int. Ed.*, 2016, **55**, 2592–2595.
- 86 W. J. Yang, T. Cai, K. G. Neoh, E. T. Kang, G. H. Dickinson, S. L. M. Teo and D. Rittschof, *Langmuir*, 2011, **27**, 7065–7076.
- 87 K. P. Reighard and M. H. Schoenfish, *Antimicrob. Agents Chemother.*, 2015, **59**, 6506–6513.
- 88 K. P. Reighard, D. B. Hill, G. A. Dixon, B. V. Worley and M. H. Schoenfish, *Biofouling*, 2015, **31**, 775–787.
- 89 J. Choi, B. J. Yang, G. N. Bae and J. H. Jung, *ACS Appl. Mater. Interfaces*, 2015, **7**, 25313–25320.
- 90 J. Dolanský, P. Henke, P. Kubát, A. Fraix, S. Sortino and J. Mosinger, *ACS Appl. Mater. Interfaces*, 2015, **7**, 22980–22989.
- 91 Z. Cao, L. Mi, J. Mendiola, J. R. Ella-Menye, L. Zhang, H. Xue and S. Jiang, *Angew. Chem., Int. Ed.*, 2012, **51**, 2602–2605.
- 92 Q. Yu, J. Cho, P. Shivapooja, L. K. Ista and G. P. Lopez, *ACS Appl. Mater. Interfaces*, 2013, **5**, 9295–9304.
- 93 M. Dargahi, Z. Hosseinidoust, N. Tufenkji and S. Omanovic, *Colloids Surf., B*, 2014, **117**, 152–157.
- 94 S. Tamura, H. Yonezawa, M. Motegi, R. Nakao, S. Yoneda, H. Watanabe, T. Yamazaki and H. Senpuku, *Oral Microbiol. Immunol.*, 2009, **24**, 152–161.
- 95 S. A. Ishijima, K. Hayama, J. P. Burton, G. Reid, M. Okada, Y. Matsushita and S. Abe, *Appl. Environ. Microbiol.*, 2012, **78**, 2190–2199.
- 96 B. W. Trautner, R. A. Hull and R. O. Darouiche, *Urology*, 2003, **61**, 1059–1062.
- 97 B. W. Trautner, R. A. Hull and R. O. Darouiche, *Curr. Opin. Infect. Dis.*, 2005, **18**, 37–41.
- 98 B. W. Trautner, R. A. Hull, J. I. Thornby and R. O. Darouiche, *Infect. Control Hosp. Epidemiol.*, 2007, **28**, 92–94.
- 99 P. Andersson, I. Engberg, G. Lidin-Janson, K. Lincoln, R. Hull, S. Hull and C. Svanborg, *Infect. Immun.*, 1991, **59**, 2915–2921.
- 100 A. Esclarin De Ruz, E. Garcia Leoni and R. Herruzo Cabrera, *J. Urol.*, 2000, **164**, 1285–1289.
- 101 A. R. Unnithan, A. Ghavami Nejad, A. R. K. Sasikala, R. G. Thomas, Y. Y. Jeong, P. Murugesan, S. Nasser, D. Wu, C. H. Park and C. S. Kim, *Chem. Eng. J.*, 2016, **287**, 640–648.
- 102 A. Vaterrodt, B. Thallinger, K. Daumann, D. Koch, G. M. Guebitz and M. Ulbricht, *Langmuir*, 2016, **32**, 1347–1359.

- 103 L.-C. Xu and C. A. Siedlecki, *Biomed. Mater.*, 2014, **9**, 035003.
- 104 L. C. Xu and C. A. Siedlecki, *Acta Biomater.*, 2012, **8**, 72–81.
- 105 L. Xu, J. W. Bauer and C. A. Siedlecki, *Colloids Surf., B*, 2014, **124**, 49–68.
- 106 L. Wang, H. Li, S. Chen, C. Nie, C. Cheng and C. Zhao, *ACS Biomater. Sci. Eng.*, 2015, **1**, 1183–1193.
- 107 Z.-Q. Shi, H.-F. Ji, H.-C. Yu, X.-L. Huang, W.-F. Zhao, S.-D. Sun and C.-S. Zhao, *Colloid Polym. Sci.*, 2016, **294**, 441–453.
- 108 J. Deng, L. Ma, X. Liu, C. Cheng, C. Nie and C. Zhao, *Adv. Mater. Interfaces*, 2016, **3**, 1500473.
- 109 A. B. Seabra and N. Durán, *J. Mater. Chem.*, 2010, **20**, 1624.
- 110 M. C. Frost, M. M. Reynolds and M. E. Meyerhoff, *Biomaterials*, 2005, **26**, 1685–1693.
- 111 M. M. Reynolds, M. C. Frost and M. E. Meyerhoff, *Free Radicals Biol. Med.*, 2004, **37**, 926–936.
- 112 S. P. Nichols, W. L. Storm, A. Koh and M. H. Schoenfish, *Adv. Drug Delivery Rev.*, 2012, **64**, 1177–1188.
- 113 E. M. Hetrick and M. H. Schoenfish, *Annu. Rev. Anal. Chem.*, 2009, **2**, 409–433.
- 114 M. M. Reynolds and G. M. Annich, *Organogenesis*, 2011, **7**, 42–49.
- 115 Y. Wang, S. Chen, Y. Pan, J. Gao, D. Tang, D. Kong and S. Wang, *J. Mater. Chem. B*, 2015, **3**, 9212–9222.
- 116 L. J. Taite, P. Yang, H.-W. Jun and J. L. West, *J. Biomed. Mater. Res., Part B*, 2007, **84**, 108–116.
- 117 I. L. A. Geenen, D. G. M. Molin, N. M. S. van den Akker, F. Jeukens, H. M. Spronk, G. W. H. Schurink and M. J. Post, *J. Tissue Eng. Regen. Med.*, 2015, **9**, 564–576.
- 118 A. W. Carpenter and M. H. Schoenfish, *Chem. Soc. Rev.*, 2012, **41**, 3742–3752.
- 119 M. Vaughn, L. Kuo and J. Liao, *Am. J. Physiol.*, 1998, **274**, 2163–2176.
- 120 K. M. Vural and M. Bayazit, *Eur. J. Vasc. Endovasc. Surg.*, 2001, **22**, 285–293.
- 121 M. C. Jen, M. C. Serrano, R. van Lith and G. A. Ameer, *Adv. Funct. Mater.*, 2012, **22**, 239–260.
- 122 J. Loscalzo, *Circ. Res.*, 2001, **88**, 756–762.
- 123 G. Walford and J. Loscalzo, *J. Thromb. Haemostasis*, 2003, **1**, 2112–2118.
- 124 J. S. Isenberg, M. J. Romeo, C. Yu, C. K. Yu, K. Nghiem, J. Monsale, M. E. Rick, D. A. Wink, W. A. Frazier and D. D. Roberts, *Blood*, 2008, **111**, 613–623.
- 125 A. Gries, C. Bode, K. Peter, A. Herr, H. Böhrer, J. Motsch and E. Martin, *Circ.*, 1998, **97**, 1481–1487.
- 126 M. W. Radomski, R. M. Palmer and S. Moncada, *Proc. Natl. Acad. Sci. U. S. A.*, 1990, **87**, 5193–5197.
- 127 D. J. Suchyta, H. Handa and M. E. Meyerhoff, *Mol. Pharm.*, 2014, **11**, 645–650.
- 128 D. O. Schairer, J. S. Chouake, J. D. Nosanchuk and A. J. Friedman, *Virulence*, 2012, **3**, 271–279.
- 129 H. Rubbo, R. Radi, M. Trujillo, R. Telleri, B. Kalyanaraman, S. Barnes, M. Kirk and B. A. Freeman, *J. Biol. Chem.*, 1994, **269**, 26066–26075.
- 130 F. C. Fang, *Nat. Rev. Microbiol.*, 2004, **2**, 820–832.
- 131 L. Ignarro and G. Buga, *Proc. Natl. Acad. Sci. U. S. A.*, 1987, **84**, 9265–9269.
- 132 S. R. Hanson, T. C. Hutsell, L. K. Keefer, D. L. Mooradian and D. J. Smith, *Adv. Pharmacol.*, 1995, **34**, 383–398.
- 133 J. O. Lundberg, M. T. Gladwin and E. Weitzberg, *Nat. Rev. Drug Discovery*, 2015, **14**, 623–641.
- 134 J. O. Lundberg, E. Weitzberg and M. T. Gladwin, *Crit. Care Med.*, 2008, **7**, 156–167.
- 135 R. Scatena, P. Bottoni, G. Martorana and B. Giardina, *Expert Opin. Invest. Drugs*, 2005, **14**, 835–846.
- 136 D. A. Riccio and M. H. Schoenfish, *Chem. Soc. Rev.*, 2012, **41**, 3731–3741.
- 137 J. A. Hrabie and L. K. Keefer, *Chem. Rev.*, 2002, **102**, 1135–1154.
- 138 V. N. Varu, N. D. Tsihliis and M. R. Kibbe, *Vasc. Endovascular Surg.*, 2009, **43**, 121–131.
- 139 J. Saraiva, S. S. Marotta-Oliveira, S. A. Cicillini, J. D. O. Eloy and J. M. Marchetti, *J. Drug Delivery*, 2011, **2011**, 936438.
- 140 S. Sortino, *Chem. Soc. Rev.*, 2010, **39**, 2903–2913.
- 141 P. G. Wang, M. Xian, X. Tang, X. Wu, Z. Wen, T. Cai and A. J. Janczuk, *Chem. Rev.*, 2002, **102**, 1091–1134.
- 142 T. Münzel, A. Daiber and A. Mülsch, *Circ. Res.*, 2005, **97**, 618–628.
- 143 K. Sydow, A. Daiber, M. Oelze, Z. Chen, M. August, M. Wendt, V. Ullrich, A. Mülsch, E. Schulz, J. F. Keaney, J. S. Stamler and T. Münzel, *J. Clin. Invest.*, 2004, **113**, 482–489.
- 144 A. Daiber, M. Oelze, M. Coldewey, M. Bachschmid, P. Wenzel, K. Sydow, M. Wendt, A. L. Kleschyov, D. Stalleicken, V. Ullrich, A. Mulsch and T. Munzel, *Mol. Pharmacol.*, 2004, **66**, 1372–1382.
- 145 L. Grossi and S. D'Angelo, *J. Med. Chem.*, 2005, **48**, 2622–2626.
- 146 L. Höfler, D. Koley, J. Wu, C. Xi and M. E. Meyerhoff, *RSC Adv.*, 2012, **2**, 6765–6767.
- 147 H. Ren, A. Colletta, D. Koley, J. Wu, C. Xi, T. C. Major, R. H. Bartlett and M. E. Meyerhoff, *Bioelectrochemistry*, 2015, **104**, 10–16.
- 148 H. Ren, J. Wu, C. Xi, N. Lehnert, T. Major, R. H. Bartlett and M. E. Meyerhoff, *ACS Appl. Mater. Interfaces*, 2014, **6**, 3779–3783.
- 149 J. R. Hwu, C. S. Yau, S.-C. Tsay and T.-I. Ho, *Tetrahedron Lett.*, 1997, **38**, 9001–9004.
- 150 A. Wan, Q. Gao and H. Li, *J. Mater. Sci. Mater. Med.*, 2009, **20**, 321–327.
- 151 S. Hong, J. Kim, Y. S. Na, J. Park, S. Kim, K. Singha, G. Il Im, D. K. Han, W. J. Kim and H. Lee, *Angew. Chem., Int. Ed.*, 2013, **52**, 9187–9191.
- 152 C. M. Maragos, D. Morley, D. A. Wink, T. M. Dunams, J. E. Saavedra, A. Hoffman, A. A. Bove, L. Isaac, J. A. Hrabie and L. K. Keefer, *J. Med. Chem.*, 1991, **34**, 3242–3247.
- 153 L. K. Keefer, R. W. Nims, K. M. Davies and D. A. Wink, *Methods Enzymol.*, 1996, **268**, 281–293.

- 154 M. M. Batchelor, S. L. Reoma, P. S. Fleser, V. K. Nuthakki, R. E. Callahan, C. J. Shanley, J. K. Politis, J. Elmore, S. I. Merz and M. E. Meyerhoff, *J. Med. Chem.*, 2003, **46**, 5153–5161.
- 155 H. Handa, E. J. Brisbois and T. C. Major, *J. Mater. Chem. B*, 2013, **1**, 3578–3587.
- 156 H. Handa, T. C. Major, E. J. Brisbois, K. A. Amoako, M. E. Meyerhoff and R. H. Bartlett, *J. Mater. Chem. B*, 2014, **2**, 1059–1067.
- 157 W. Cai, J. Wu, C. Xi and M. E. Meyerhoff, *Biomaterials*, 2012, **33**, 7933–7944.
- 158 H. K. Makadia and S. J. Siegel, *Polymer*, 2011, **3**, 1377–1397.
- 159 J. S. Stamler, O. Jaraki, J. Osborne, D. I. Simon, J. Keaney, J. Vita, D. Singel, C. R. Valeri and J. Loscalzo, *Proc. Natl. Acad. Sci. U. S. A.*, 1992, **89**, 7674–7677.
- 160 D. Giustarini, A. Milzani, R. Colombo, I. Dalle-Donne and R. Rossi, *Clin. Chim. Acta*, 2003, **330**, 85–98.
- 161 X. Duan and R. S. Lewis, *Biomaterials*, 2002, **23**, 1197–1203.
- 162 E. J. Brisbois, H. Handa, T. C. Major, R. H. Bartlett and M. E. Meyerhoff, *Biomaterials*, 2013, **34**, 6957–6966.
- 163 Y. Wo, Z. Li, E. J. Brisbois, A. Colletta, J. Wu, T. C. Major, C. Xi, R. H. Bartlett, A. J. Matzger and M. E. Meyerhoff, *ACS Appl. Mater. Interfaces*, 2015, **7**, 22218–22227.
- 164 D. L. H. Williams, *Chem. Commun.*, 1996, 1085–1091.
- 165 D. L. H. Williams, *Transition Met. Chem.*, 1996, **21**, 189–191.
- 166 D. L. Williams, *Acc. Chem. Res.*, 1999, **32**, 869–876.
- 167 K. Szacilowski and Z. Stasicka, *Prog. React. Kinet. Mech.*, 2001, **26**, 1–58.
- 168 R. J. Singh, N. Hogg, J. Joseph and B. Kalyanaraman, *J. Biol. Chem.*, 1996, **271**, 18596–18603.
- 169 C. T. Aravindakumar, M. M. Veleparampil and U. K. Aravind, *Adv. Phys. Chem.*, 2009, **2009**, 890346.
- 170 J. McAninly, D. L. H. Williams, S. C. Askew, A. R. Butler and C. Russell, *J. Chem. Soc., Chem. Commun.*, 1993, 1758–1759.
- 171 S. Hwang and M. E. Meyerhoff, *Biomaterials*, 2008, **29**, 2443–2452.
- 172 W. Cha and M. E. Meyerhoff, *Biomaterials*, 2007, **28**, 19–27.
- 173 J. Yang, J. L. Welby and M. E. Meyerhoff, *Langmuir*, 2008, **24**, 10265–10272.
- 174 W. Cai, J. Wu, C. Xi, A. J. Ashe and M. E. Meyerhoff, *Biomaterials*, 2011, **32**, 7774–7784.
- 175 A. J. Holmes and D. L. H. Williams, *Chem. Commun.*, 1998, 1711–1712.
- 176 A. J. Holmes and D. L. H. Williams, *J. Chem. Soc., Trans. 2*, 2000, 1639–1644.
- 177 D. Jourdeuil, F. S. Laroux, A. M. Miles, D. A. Wink and M. B. Grisham, *Arch. Biochem. Biophys.*, 1999, **361**, 323–330.
- 178 A. B. Seabra, in *Nanocosmetics and Nanomedicines*, ed. R. Beck, S. Guterres and A. Pohlmann, Springer Berlin Heidelberg, Berlin, Heidelberg, 2011, pp. 253–268.
- 179 R. Vercelino, T. M. Cunha, E. S. Ferreira, F. Q. Cunha, S. H. Ferreira and M. G. De Oliveira, *J. Mater. Sci. Mater. Med.*, 2013, **24**, 2157–2169.
- 180 F. S. Schanuel, K. S. Raggio Santos, A. Monte-Alto-Costa and M. G. De Oliveira, *Colloids Surf., B*, 2015, **130**, 182–191.
- 181 M. G. de Oliveira, *Basic Clin. Pharmacol. Toxicol.*, 2016.
- 182 T. R. Borthwick, G. D. Benson and H. J. Schugar, *J. Lab. Clin. Med.*, 1980, **95**, 575–580.
- 183 V. Parameshvara, *Br. J. Ind. Med.*, 1967, **24**, 73–76.
- 184 K. A. Graeme and C. V. Pollack, *J. Emerg. Med.*, 1998, **16**, 45–56.
- 185 M. M. Jones, A. D. Weaver and W. L. Weller, *Res. Commun. Chem. Pathol. Pharmacol.*, 1978, **22**, 581–588.
- 186 N. Arulsamy, D. S. Bohle, J. A. Butt, G. J. Irvine, P. A. Jordan and E. Sagan, *J. Am. Chem. Soc.*, 1999, **121**, 7115–7123.
- 187 E. J. Brisbois, R. P. Davis, A. M. Jones, T. C. Major, R. H. Bartlett, M. E. Meyerhoff and H. Handa, *J. Mater. Chem. B*, 2015, **3**, 1639–1645.
- 188 I. L. Megson, S. Morton, I. R. Greig, F. A. Mazzei, R. A. Field, A. R. Butler, G. Caron, A. Gasco, R. Fruttero and D. J. Webb, *Br. J. Pharmacol.*, 1999, **126**, 639–648.
- 189 I. L. Megson, *Drugs Future*, 2002, **27**, 777.
- 190 A. Ketchum, M. Kappler, J. Wu, C. Xi and M. E. Meyerhoff, *J. Mater. Chem. B*, 2015, **4**, 422–430.
- 191 Y. S. Jo, A. J. van der Vlies, J. Gantz, T. N. Thacher, S. Antonijevic, S. Cavadini, D. Demurtas, N. Stergiopoulos and J. A. Hubbell, *J. Am. Chem. Soc.*, 2009, **131**, 14413–14418.
- 192 N. Kanayama, K. Yamaguchi and Y. Nagasaki, *Chem. Lett.*, 2010, **39**, 1008–1009.
- 193 F. Cavaliere, I. Finelli, M. Tortora, P. Mozetic, E. Chiessi, F. Polizio, T. B. Brismar and G. Paradossi, *Chem. Mater.*, 2008, **20**, 3254–3258.
- 194 J. A. Hrabie, J. E. Saavedra, P. P. Roller, G. J. Southan and L. K. Keefer, *Bioconjugate Chem.*, 1999, **10**, 838–842.
- 195 D. I. Simon, M. E. Mullins, L. Jia, B. Gaston, D. J. Singel and J. S. Stamler, *Proc. Natl. Acad. Sci. U. S. A.*, 1996, **93**, 4736–4741.
- 196 J. F. Ewing, D. V. Young, D. R. Janero, D. S. Garvey and T. A. Grinnell, *J. Pharmacol. Exp. Ther.*, 1997, **283**, 947–954.
- 197 Y. Ishima, T. Akaike, U. Kragh-Hansen, S. Hiroshima, T. Sawa, A. Suenaga, T. Maruyama, T. Kai and M. Otagiri, *J. Biol. Chem.*, 2008, **283**, 34966–34975.
- 198 H. Katsumi, M. Nishikawa, F. Yamashita and M. Hashida, *J. Pharmacol. Exp. Ther.*, 2005, **314**, 1117–1124.
- 199 S.-L. Huang, P. H. Kee, H. Kim, M. R. Moody, S. M. Chrzanowski, R. C. Macdonald and D. D. McPherson, *J. Am. Coll. Cardiol.*, 2009, **54**, 652–659.
- 200 M. C. Frost and M. E. Meyerhoff, *J. Am. Chem. Soc.*, 2004, **126**, 1348–1349.
- 201 M. C. Frost and M. E. Meyerhoff, *J. Biomed. Mater. Res., Part A*, 2005, **72**, 409–419.
- 202 A. W. Carpenter, D. L. Slomberg, K. S. Rao and M. H. Schoenfish, *ACS Nano*, 2011, **5**, 7235–7244.
- 203 M. H. Kafshgari, A. Cavallaro, B. Delalat, F. J. Harding, S. J. McInnes, E. Mäkilä, J. Salonen, K. Vasilev and N. H. Voelcker, *Nanoscale Res. Lett.*, 2014, **9**, 333.

- 204 D. L. Slomberg, Y. Lu, A. D. Broadnax, R. A. Hunter, A. W. Carpenter and M. H. Schoenfish, *ACS Appl. Mater. Interfaces*, 2013, **5**, 9322–9329.
- 205 A. R. Rothrock, R. L. Donkers and M. H. Schoenfish, *Society*, 2005, **127**, 9362–9363.
- 206 M. A. Polizzi, N. A. Stasko and M. H. Schoenfish, *Langmuir*, 2007, **23**, 4938–4943.
- 207 G. Lautner, M. E. Meyerhoff and S. P. Schwendeman, *J. Controlled Release*, 2016, **225**, 133–139.
- 208 P. S. Wheatley, A. R. Butler, M. S. Crane, S. Fox, B. Xiao, A. G. Rossi, I. L. Megson and R. E. Morris, *J. Am. Chem. Soc.*, 2006, **128**, 502–509.
- 209 M. Neidrauer, U. K. Ercan, A. Bhattacharyya, J. Samuels, J. Sedlak, R. Trikha, K. A. Barbee, M. S. Weingarten and S. G. Joshi, *J. Med. Microbiol.*, 2014, **63**, 203–209.
- 210 J. L. Harding and M. M. Reynolds, *J. Am. Chem. Soc.*, 2012, **134**, 3330–3333.
- 211 J. L. Harding and M. M. Reynolds, *J. Mater. Chem. B*, 2014, **2**, 2530–2536.
- 212 J. L. Harding, J. M. Metz and M. M. Reynolds, *Adv. Funct. Mater.*, 2014, **24**, 7503–7509.
- 213 M. J. Neufeld, J. L. Harding and M. M. Reynolds, *ACS Appl. Mater. Interfaces*, 2015, **7**, 26742–26750.
- 214 N. A. Stasko, T. H. Fischer and M. H. Schoenfish, *Biomacromolecules*, 2008, **9**, 834–841.
- 215 C. J. Backlund, B. V. Worley and M. H. Schoenfish, *Acta Biomater.*, 2016, **29**, 198–205.
- 216 W. L. Storm, J. A. Johnson, B. V. Worley, D. L. Slomberg and M. H. Schoenfish, *J. Biomed. Mater. Res., Part A*, 2014, 1–11.
- 217 D. A. Riccio, K. P. Dobmeier, E. M. Hetrick, B. J. Privett, H. S. Paul and M. H. Schoenfish, *Biomaterials*, 2009, **30**, 4494–4502.
- 218 P. Nacharaju, C. Tuckman-Vernon, K. E. Maier, J. Chouake, A. Friedman, P. Cabrales and J. M. Friedman, *Nitric Oxide*, 2012, **27**, 150–160.
- 219 P. N. Coneski, J. A. Nash and M. H. Schoenfish, *ACS Appl. Mater. Interfaces*, 2011, **3**, 426–432.
- 220 J.-W. Yoo, H. Nurhasni, J. Cao, M. Choi, I. Kim, B. Luel Lee and Y. Jung, *Int. J. Nanomed.*, 2015, **10**, 3065–3080.
- 221 Y. Lu, D. L. Slomberg and M. H. Schoenfish, *Biomaterials*, 2014, **35**, 1716–1724.
- 222 J. O. Kim, J. K. Noh, R. K. Thapa, N. Hasan, M. Choi, J. H. Kim, J. H. Lee, S. K. Ku and J. W. Yoo, *Int. J. Biol. Macromol.*, 2015, **79**, 217–225.
- 223 C. Vogt, Q. Xing, W. He, B. Li, M. C. Frost and F. Zhao, *Biomacromolecules*, 2013, **14**, 2521–2530.
- 224 P. G. Parzuchowski, M. C. Frost and M. E. Meyerhoff, *J. Am. Chem. Soc.*, 2002, **124**, 12182–12191.
- 225 A. B. Seabra, R. Da Silva, G. F. P. De Souza and M. G. De Oliveira, *Artif. Organs*, 2008, **32**, 262–267.
- 226 J. P. Yapor, A. Lutzke, A. Pegalajar-Jurado, B. H. Neufeld, V. B. Damodaran and M. M. Reynolds, *J. Mater. Chem. B*, 2015, **3**, 9233–9241.
- 227 G. E. Gierke, M. Nielsen and M. C. Frost, *Sci. Technol. Adv. Mater.*, 2011, **12**, 055007.
- 228 A. Pegalajar-Jurado, K. A. Wold, J. M. Joslin, B. H. Neufeld, K. A. Arabea, L. A. Suazo, S. L. McDaniel, R. A. Bowen and M. M. Reynolds, *J. Controlled Release*, 2015, **220**, 617–623.
- 229 A. Wan, Q. Gao and H. Li, *J. Mater. Sci. Mater. Med.*, 2008, **20**, 321–327.
- 230 J. Park, J. Kim, K. Singha, D. K. Han, H. Park and W. J. Kim, *Biomaterials*, 2013, **34**, 8766–8775.
- 231 J. Kim, Y. Lee, K. Singha, H. W. Kim, J. H. Shin, S. Jo, D. K. Han and W. J. Kim, *Bioconjugate Chem.*, 2011, **22**, 1031–1038.
- 232 A. B. Seabra, A. Fitzpatrick, J. Paul, M. G. De Oliveira and R. Weller, *Br. J. Dermatol.*, 2004, **151**, 977–983.
- 233 K. Masters, S. Leibovich, P. Belem, J. L. West and L. Poole-Warren, *Wound Repair Regen.*, 2002, **10**, 286–294.
- 234 M. M. Reynolds, J. A. Hrabie, B. K. Oh, J. K. Politis, M. L. Citro, L. K. Keefer and M. E. Meyerhoff, *Biomacromolecules*, 2006, **7**, 987–994.
- 235 M. M. Reynolds, J. E. Saavedra, B. M. Showalter, C. A. Valdez, A. P. Shanklin, B. K. Oh, L. K. Keefer and M. E. Meyerhoff, *J. Mater. Chem.*, 2010, **20**, 3107–2114.
- 236 B. Parzuchowska and P. Parzuchowski, *Polimery*, 2014, **59**, 105–194.
- 237 H. Zhang, G. M. Annich, J. Miskulin, K. Stankiewicz, K. Osterholzer, S. I. Merz, R. H. Bartlett and M. E. Meyerhoff, *J. Am. Chem. Soc.*, 2003, **125**, 5015–5024.
- 238 J. E. Saavedra, M. N. Booth, J. A. Hrabie, K. M. Davies and L. K. Keefer, *J. Org. Chem.*, 1999, **64**, 5124–5131.
- 239 H. Zhang, G. M. Annich, J. Miskulin, K. Osterholzer, S. I. Merz, R. H. Bartlett and M. E. Meyerhoff, *Biomaterials*, 2002, **23**, 1485–1494.
- 240 D. J. Smith, D. Chakravarthy, S. Pulfer, M. L. Simmons, J. A. Hrabie, M. L. Citro, J. E. Saavedra, K. M. Davies, T. C. Hutsell, D. L. Mooradian, S. R. Hanson and L. K. Keefer, *J. Med. Chem.*, 1996, **39**, 1148–1156.
- 241 Y. Kou and A. Wan, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 2337–2341.
- 242 Y. Kang, J. Kim, Y. M. Lee, S. Im, H. Park and W. J. Kim, *J. Controlled Release*, 2015, **220**, 624–630.
- 243 N. A. Stasko and M. H. Schoenfish, *J. Am. Chem. Soc.*, 2006, **128**, 8265–8271.
- 244 C. W. McCarthy, J. Goldman and M. C. Frost, *ACS Appl. Mater. Interfaces*, 2016, **8**, 5898–5905.
- 245 V. B. Damodaran, L. W. Place, M. J. Kipper and M. M. Reynolds, *J. Mater. Chem.*, 2012, **22**, 23038.
- 246 T. Kean and M. Thanou, *Adv. Drug Delivery Rev.*, 2010, **62**, 3–11.
- 247 C. Wang, F. Yang, Z. Xu, D. Shi, D. Chen, J. Dai, N. Gu and Q. Jiang, *Thromb. Res.*, 2013, **131**, e31–e38.
- 248 L. A. Tai, Y. C. Wang and C. S. Yang, *Nitric Oxide - Biol. Chem.*, 2010, **23**, 60–64.
- 249 J. J. Koehler, J. Zhao, S. S. Jedlicka, D. M. Porterfield and J. L. Rickus, *J. Phys. Chem. B*, 2008, **112**, 15086–15093.
- 250 H. S. Jeh, S. Lu and S. C. George, *J. Microencapsulation*, 2004, **21**, 3–13.

- 251 C. Wischke and S. P. Schwendeman, *Int. J. Pharm.*, 2008, **364**, 298–327.
- 252 S. M. Shishido, A. B. Seabra, W. Loh and M. G. de Oliveira, *Biomaterials*, 2003, **24**, 3543–3553.
- 253 M. G. de Oliveira, S. M. Shishido, A. B. Seabra and N. H. Morgon, *J. Phys. Chem. A*, 2002, **106**, 8963–8970.
- 254 H. Gappa-Fahlenkamp and R. S. Lewis, *Biomaterials*, 2005, **26**, 3479–3485.
- 255 T. C. Major, D. O. Brant, C. P. Burney, K. A. Amoako, G. M. Annich, M. E. Meyerhoff, H. Handa and R. H. Bartlett, *Biomaterials*, 2011, **32**, 5957–5969.
- 256 S. C. Puiu, Z. Zhou, C. C. White, L. J. Neubauer, Z. Zhang, L. E. Lange, J. A. Mansfield, M. E. Meyerhoff and M. M. Reynolds, *J. Biomed. Mater. Res., Part B*, 2009, **91**, 203–212.
- 257 B. K. Oh and M. E. Meyerhoff, *Biomaterials*, 2004, **25**, 283–293.
- 258 V. Wonoputri, C. Gunawan, S. Liu, N. Barraud, L. H. Yee, M. Lim and R. Amal, *ACS Appl. Mater. Interfaces*, 2015, **7**, 22148–22156.
- 259 H. Ren, M. A. Coughlin, T. C. Major, S. Aiello, A. Rojas Pena, R. H. Bartlett and M. E. Meyerhoff, *Anal. Chem.*, 2015, 8067–8072.
- 260 Y. Wu, Z. Zhou and M. E. Meyerhoff, *J. Biomed. Mater. Res., Part A*, 2007, **81**, 956–963.
- 261 A. M. Skrzypchak, N. G. Lafayette, R. H. Bartlett, Z. Zhou, M. C. Frost, M. E. Meyerhoff, M. M. Reynolds and G. M. Annich, *Perfusion*, 2007, **22**, 193–200.
- 262 C. W. McCarthy, R. J. Guillory, J. Goldman and M. C. Frost, *ACS Appl. Mater. Interfaces*, 2016, **8**, 10128–10135.
- 263 B. M. Bloom, J. Grundlingh, J. P. Bestwick and T. Harris, *Eur. J. Emerg. Med.*, 2014, **21**, 81–88.
- 264 D. S. Martin and M. P. W. Grocott, *Crit. Care Med.*, 2013, **41**, 423–432.
- 265 The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, *N. Engl. J. Med.*, 2008, **359**, 1464–1476.
- 266 K. E. A. Burns and A. McLaren, *Can. Respir. J.*, 2009, **16**, 163–165.
- 267 S. M. Marxer, M. E. Robbins and M. H. Schoenfisch, *Analyst*, 2005, **130**, 206–212.
- 268 K. A. Mowery, M. H. Schoenfisch, N. Baliga, J. A. Wahr and M. E. Meyerhoff, *Electroanalysis*, 1999, **11**, 681–686.
- 269 M. H. Schoenfisch, K. A. Mowery, M. V. Rader, N. Baliga, J. A. Wahr and M. E. Meyerhoff, *Anal. Chem.*, 2000, **72**, 1119–1126.
- 270 M. C. Frost, S. M. Rudich, H. Zhang, M. A. Maraschio and M. E. Meyerhoff, *Anal. Chem.*, 2002, **74**, 5942–5947.
- 271 Y. Wu, A. P. Rojas, G. W. Griffith, A. M. Skrzypchak, N. Lafayette, R. H. Bartlett and M. E. Meyerhoff, *Sens. Actuators, B*, 2007, **121**, 36–46.
- 272 Q. Yan, T. C. Major, R. H. Bartlett and M. E. Meyerhoff, *Biosens. Bioelectron.*, 2011, **26**, 4276–4282.
- 273 A. K. Wolf, Y. Qin, T. C. Major and M. E. Meyerhoff, *Chin. Chem. Lett.*, 2015, **26**, 464–468.
- 274 J. H. Shin, S. M. Marxer and M. H. Schoenfisch, *Anal. Chem.*, 2004, **76**, 4543–4549.
- 275 M. C. Frost, A. K. Wolf and M. E. Meyerhoff, in *Detection Challenges in Clinical Diagnostics*, 2013, pp. 129–155.
- 276 R. K. Meruva and M. E. Meyerhoff, *Biosens. Bioelectron.*, 1998, **13**, 201–212.
- 277 K. P. Dobmeier, G. W. Charville and M. H. Schoenfisch, *Anal. Chem.*, 2006, **78**, 7461–7466.
- 278 M. C. Frost, M. M. Batchelor, Y. Lee, H. Zhang, Y. Kang, B. Oh, G. S. Wilson, R. Gifford, S. M. Rudich and M. E. Meyerhoff, *Microchem. J.*, 2003, **74**, 277–288.
- 279 T. C. Major, D. O. Brant, M. M. Reynolds, R. H. Bartlett, M. E. Meyerhoff, H. Handa and G. M. Annich, *Biomaterials*, 2010, **31**, 2736–2745.
- 280 T. C. Major, H. Handa, G. M. Annich and R. H. Bartlett, *J. Biomater. Appl.*, 2014, **29**, 479–501.
- 281 J. S. Stamler, *Circ. Res.*, 2004, **94**, 414–417.
- 282 A. Ghaffari, C. C. Miller, B. McMullin and A. Ghahary, *Nitric Oxide*, 2006, **14**, 21–29.
- 283 D. P. Arora, S. Hossain, Y. Xu and E. M. Boon, *Biochemistry*, 2015, **54**, 3717–3728.
- 284 Y. Lu, D. Slomberg, B. Sun and M. Schoenfisch, *Small*, 2013, **9**, 2189–2198.
- 285 R. Vumma, C. S. Bang, R. Kruse, K. Johansson and K. Persson, *J. Antibiot.*, 2015, 1–4.
- 286 B. B. McMullin, D. R. Chittock, D. L. Roscoe, H. Garcha, L. Wang and C. C. Miller, *Respir. Care*, 2005, **50**, 1451–1456.
- 287 N. Barraud, M. J. Kelso, S. A. Rice and S. Kjelleberg, *Curr. Pharm. Des.*, 2015, **21**, 31–42.
- 288 N. Barraud, D. J. Hassett, S.-H. Hwang, S. A. Rice, S. Kjelleberg and J. S. Webb, *J. Bacteriol.*, 2006, **188**, 7344–7353.
- 289 N. Barraud, M. V. Storey, Z. P. Moore, J. S. Webb, S. A. Rice and S. Kjelleberg, *Microb. Biotechnol.*, 2009, **2**, 370–378.
- 290 B. J. Nablo and M. H. Schoenfisch, *J. Biomed. Mater. Res., Part A*, 2003, **67**, 1276–1283.
- 291 E. J. Brisbois, J. Bayliss, J. Wu, T. C. Major, C. Xi, S. C. Wang, R. H. Bartlett, H. Handa and M. E. Meyerhoff, *Acta Biomater.*, 2014, 4136–4142.
- 292 M. R. Schäffer, P. A. Efron, F. J. Thornton, K. Klingel, S. S. Gross and A. Barbul, *J. Immunol.*, 1997, **158**, 2375–2381.
- 293 M. B. Witte and A. Barbul, *Am. J. Surg.*, 2002, **183**, 406–412.
- 294 H. P. Shi, D. T. Efron, D. Most and A. Barbul, *Surgery*, 2001, **130**, 225–229.
- 295 G. Richardson and N. Benjamin, *Clin. Sci.*, 2002, **105**, 99–105.
- 296 G. E. Romanowicz, W. He, M. Nielsen and M. C. Frost, *Redox Biol.*, 2013, **1**, 332–339.
- 297 T.-K. Nguyen, R. Selvanayagam, K. K. K. Ho, R. Chen, S. K. Kutty, S. A. Rice, N. Kumar, N. Barraud, H. T. T. Duong and C. Boyer, *Chem. Sci.*, 2016, **7**, 1016–1027.